Bupropion (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bupropion" in English language version.

refsWebsite

Global rank English rank

206nih.gov

4^th place

148doi.org

2^nd place

53web.archive.org

1^st place

32semanticscholar.org

11^th place

8^th place

15fda.gov

447^th place

338^th place

6harvard.edu

18^th place

17^th place

5handle.net

102^nd place

76^th place

5worldcat.org

5^th place

4europa.eu

68^th place

117^th place

3books.google.com

3^rd place

2canada.ca

1,712^th place

1,063^rd place

2medicines.org.uk

3,823^rd place

2,387^th place

2clincalc.com

3,912^th place

2,496^th place

1drugs.com

399^th place

333^rd place

1tga.gov.au

3,984^th place

2,622^nd place

1in.gov.br

3,151^st place

5,932^nd place

1exlibrisgroup.com

9,042^nd place

5,814^th place

1unil.ch

9,112^th place

7,304^th place

1uspto.gov

1,459^th place

991^st place

1cardiff.ac.uk

low place

7,039^th place

1primarypsychiatry.com

low place

1cam.ac.uk

670^th place

480^th place

1lww.com

2,769^th place

3,314^th place

1unc.edu

1,538^th place

1,042^nd place

1bindingdb.org

low place

1d1wqtxts1xzle7.cloudfront.net

low place

1fiocruz.br

low place

1mhmedical.com

6,846^th place

4,957^th place

1drugbank.com

low place

1vcu.edu

7,721^st place

4,593^rd place

1emedexpert.com

low place

1drugabuse.gov

6,166^th place

5,476^th place

1cnn.com

28^th place

26^th place

1peoplespharmacy.com

low place

1nbcnews.com

137^th place

101^st place

1medscape.com

719^th place

636^th place

1nytimes.com

7^th place

1pharmaceutical-journal.com

low place

1psu.edu

207^th place

136^th place

1globalnews.ca

985^th place

583^rd place

1garant.ru

1,937^th place

7,777^th place

1sante.fr

8,603^rd place

low place

bindingdb.org (Global: low place; English: low place)

Liu T. "BindingDB BDBM50048392 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one::BUPROPION::BUPROPION HYDROCHLORIDE::CHEMBL894::US9944618, Compound ID No. 176". BindingDB. Retrieved 19 August 2024.

books.google.com (Global: 3^rd place; English: 3^rd place)

DeBattista C (16 June 2022). "Other Antidepressants: Bupropion, Mirtazapine, and Trazodone". In Nemeroff CB, Schatzberg AF, Rasgon N, Strakowski SM (eds.). The American Psychiatric Association Publishing Textbook of Mood Disorders, Second Edition. American Psychiatric Pub. pp. 365–374. ISBN 978-1-61537-331-4. OCLC 1249799493. Archived from the original on 8 March 2023. Retrieved 27 August 2022.
Dye LR, Murphy C, Calello DP, Levine MD, Skolnik A (2017). Case Studies in Medical Toxicology: From the American College of Medical Toxicology. Springer. p. 85. ISBN 978-3-319-56449-4. Archived from the original on 29 August 2021. Retrieved 5 June 2020.
Schweizerischer Apotheker-Verein (2004). Index Nominum: International Drug Directory. Medpharm Scientific Publishers. p. 173. ISBN 978-3-88763-101-7. Retrieved 4 August 2024.

cam.ac.uk (Global: 670^th place; English: 480^th place)

api.repository.cam.ac.uk

Hailwood JM (27 September 2018). Novel approaches towards pharmacological enhancement of motivation (Thesis). University of Cambridge. pp. 13–14. doi:10.17863/CAM.40216. Bupropion also acts as a dopamine reuptake inhibitor (Dwoskin et al. 2006), and has been used as a treatment for depression as well as a smoking cessation aid (Stahl et al. 2004). Bupropion has been shown to produce a dose-dependent increase in PR breakpoints (Bruijnzeel & Markou 2003). Furthermore, systemic administration of bupropion increases the selection of the high-effort, high-reward option in a PR-choice task in rats (Randall, Lee, Podurgiel, et al. 2014). Bupropion is also effective at rescuing motivational impairments in rodents. Administration of bupropion can rescue deficits in effort-related decision-making induced by pre-treatment with tetrabenazine (Randall, Lee, Nunes, et al. 2014; Nunes, Randall, Hart, et al. 2013) and the pro-inflammatory cytokine interleukin-6 (Yohn, Arif, et al. 2016). Bupropion has been reported to improve symptoms of apathy in cases of acquired brain injury, major depression (Corcoran et al. 2004), and frontotemporal dementia (Lin et al. 2016). | However, several larger placebo-controlled studies suggest only limited effects of bupropion. In a study of 40 patients with schizophrenia, bupropion was found to have no significant effect on apathy or negative symptoms as a whole (Yassini et al. 2014). Furthermore, in a recent RCT of bupropion in HD, apathy was not significantly affected by the drug (Gelderblom et al. 2017). | It is not clear whether bupropion lacks clinical efficacy, whether bupropion as a whole is not effective at treating motivational impairments, or is not effective in the clinical populations tested.

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

health-products.canada.ca

"Wellbutrin Product information". Health Canada. 25 April 2012. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
"Zyban Product information". Health Canada. 25 April 2012. Archived from the original on 9 January 2023. Retrieved 9 January 2023.

cardiff.ac.uk (Global: low place; English: 7,039^th place)

orca.cardiff.ac.uk

Monden R, Roest AM, van Ravenzwaaij D, Wagenmakers EJ, Morey R, Wardenaar KJ, et al. (August 2018). "The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews" (PDF). Journal of Affective Disorders. 235: 393–398. doi:10.1016/j.jad.2018.04.040. hdl:11370/842b1441-d0f3-4797-b95b-3a6a72262150. PMID 29677603. S2CID 5011570. Archived (PDF) from the original on 27 February 2022. Retrieved 13 December 2021.

clincalc.com (Global: 3,912^th place; English: 2,496^th place)

"Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
"Bupropion Drug Usage Statistics, United States, 2014 - 2023". ClinCalc. Retrieved 12 August 2025.

cnn.com (Global: 28^th place; English: 26^th place)

"Seasonal affective disorder drug Wellbutrin XL wins approval". CNN. 14 June 2006. Archived from the original on 30 June 2007. Retrieved 19 August 2007.

d1wqtxts1xzle7.cloudfront.net (Global: low place; English: low place)

Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1" (PDF). J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID 26791601. Archived from the original (PDF) on 9 May 2025.

doi.org (Global: 2^nd place; English: 2^nd place)

Costa R, Oliveira NG, Dinis-Oliveira RJ (August 2019). "Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects". Drug Metabolism Reviews. 51 (3): 293–313. doi:10.1080/03602532.2019.1620763. PMID 31124380. S2CID 163167323.
Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. (2005). "15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL". Primary Care Companion to the Journal of Clinical Psychiatry. 7 (3): 106–113. doi:10.4088/pcc.v07n0305. PMC 1163271. PMID 16027765.
Masters AR, Gufford BT, Lu JB, Metzger IF, Jones DR, Desta Z (August 2016). "Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers". The Journal of Pharmacology and Experimental Therapeutics. 358 (2): 230–238. doi:10.1124/jpet.116.232876. PMC 4959100. PMID 27255113.
Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK (April 2016). "Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant". Therapeutic Advances in Psychopharmacology. 6 (2): 99–144. doi:10.1177/2045125316629071. PMC 4837968. PMID 27141292.
Arandjelovic K, Eyre HA, Lavretsky H (October 2016). "Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports". The American Journal of Geriatric Psychiatry. 24 (10): 913–917. doi:10.1016/j.jagp.2016.05.010. PMC 5540329. PMID 27591914.
Dhillon S, Yang LP, Curran MP (2008). "Bupropion: a review of its use in the management of major depressive disorder". Drugs. 68 (5): 653–689. doi:10.2165/00003495-200868050-00011. PMID 18370448. S2CID 195687060.
Steinert T, Fröscher W (July 2018). "Epileptic Seizures Under Antidepressive Drug Treatment: Systematic Review". Pharmacopsychiatry. 51 (4): 121–135. doi:10.1055/s-0043-117962. PMID 28850959. S2CID 22436728.
Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, et al. (February 2005). "Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder". The Journal of Clinical Psychiatry. 66 (2): 253–259. doi:10.4088/jcp.v66n0215. PMID 15705013.
Voican CS, Corruble E, Naveau S, Perlemuter G (April 2014). "Antidepressant-induced liver injury: a review for clinicians". The American Journal of Psychiatry. 171 (4): 404–415. doi:10.1176/appi.ajp.2013.13050709. PMID 24362450.
Kumar S, Kodela S, Detweiler JG, Kim KY, Detweiler MB (November–December 2011). "Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature". General Hospital Psychiatry. 33 (6): 612–617. doi:10.1016/j.genhosppsych.2011.07.001. PMID 21872337.
Nelson JC, Spyker DA (May 2017). "Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000–2014". The American Journal of Psychiatry. 174 (5): 438–450. doi:10.1176/appi.ajp.2016.16050523. PMID 28135844.
De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E (March 2021). "A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants". Drug Safety. 44 (3): 291–312. doi:10.1007/s40264-020-01027-x. PMID 33354752. S2CID 229357583. Archived from the original on 7 March 2023. Retrieved 17 May 2022.
Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, et al. (October 2021). "Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants" (PDF). The World Journal of Biological Psychiatry. 22 (8): 561–628. doi:10.1080/15622975.2021.1878427. PMID 33977870. S2CID 234472488. Archived (PDF) from the original on 5 May 2022. Retrieved 10 April 2022.
Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI (2014). "Bupropion and bupropion analogs as treatments for CNS disorders". Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Advances in Pharmacology. Vol. 69. Academic Press. pp. 177–216. doi:10.1016/B978-0-12-420118-7.00005-6. ISBN 978-0-12-420118-7. PMID 24484978.
Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C (October 2017). "Bupropion for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2017 (10): CD009504. doi:10.1002/14651858.CD009504.pub2. PMC 6485546. PMID 28965364.{{cite journal}}: CS1 maint: article number as page number (link)
Gautam M, Patel S, Zarkowski P (January 2022). "Practice patterns of bupropion co-prescription with antipsychotic medications". J Addict Dis. 40 (4): 481–488. doi:10.1080/10550887.2022.2028531. PMID 35068363. S2CID 246238087.
Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. (March 2021). "Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials". Expert Opinion on Emerging Drugs. 26 (1): 63–74. doi:10.1080/14728214.2021.1898588. PMID 33682569. S2CID 232141396.
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. (February 2009). "Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis". Lancet. 373 (9665): 746–758. doi:10.1016/S0140-6736(09)60046-5. PMID 19185342. S2CID 35858125.
Monden R, Roest AM, van Ravenzwaaij D, Wagenmakers EJ, Morey R, Wardenaar KJ, et al. (August 2018). "The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews" (PDF). Journal of Affective Disorders. 235: 393–398. doi:10.1016/j.jad.2018.04.040. hdl:11370/842b1441-d0f3-4797-b95b-3a6a72262150. PMID 29677603. S2CID 5011570. Archived (PDF) from the original on 27 February 2022. Retrieved 13 December 2021.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. (April 2018). "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet. 391 (10128): 1357–1366. doi:10.1016/S0140-6736(17)32802-7. PMC 5889788. PMID 29477251.
Hengartner MP, Jakobsen JC, Sørensen A, Plöderl M (2020). "Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials". PLOS ONE. 15 (2): e0229381. Bibcode:2020PLoSO..1529381H. doi:10.1371/journal.pone.0229381. PMC 7043778. PMID 32101579.{{cite journal}}: CS1 maint: article number as page number (link)
Stone MB, Yaseen ZS, Miller BJ, Richardville K, Kalaria SN, Kirsch I (August 2022). "Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis". BMJ. 378: e067606. doi:10.1136/bmj-2021-067606. PMC 9344377. PMID 35918097.{{cite journal}}: CS1 maint: article number as page number (link)
Turner EH, Cipriani A, Furukawa TA, Salanti G, de Vries YA (January 2022). "Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials". PLOS Med. 19 (1): e1003886. doi:10.1371/journal.pmed.1003886. PMC 8769343. PMID 35045113.{{cite journal}}: CS1 maint: article number as page number (link)
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (January 2008). "Selective publication of antidepressant trials and its influence on apparent efficacy". N Engl J Med. 358 (3): 252–60. doi:10.1056/NEJMsa065779. PMID 18199864.
Gartlehner G, Nussbaumer-Streit B, Gaynes BN, Forneris CA, Morgan LC, Greenblatt A, et al. (March 2019). "Second-generation antidepressants for preventing seasonal affective disorder in adults". The Cochrane Database of Systematic Reviews. 3 (4): CD011268. doi:10.1002/14651858.CD011268.pub3. PMC 6422318. PMID 30883669.{{cite journal}}: CS1 maint: article number as page number (link)
Li DJ, Tseng PT, Chen YW, Wu CK, Lin PY (March 2016). "Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines". Medicine. 95 (13): e3165. doi:10.1097/MD.0000000000003165. PMC 4998539. PMID 27043678.{{cite journal}}: CS1 maint: article number as page number (link)
Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, et al. (August 2008). "Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies". The Journal of Clinical Psychiatry. 69 (8): 1287–1292. doi:10.4088/JCP.v69n0812. PMID 18605812. S2CID 25267685.
Naguy A, Badr BHM (October 2022). "Bupropion-myth-busting!". CNS Spectr. 27 (5): 545–546. doi:10.1017/S1092852921000365. PMID 33843549. S2CID 233212535.
Ruberto VL, Jha MK, Murrough JW (June 2020). "Pharmacological Treatments for Patients with Treatment-Resistant Depression". Pharmaceuticals. 13 (6): 116. doi:10.3390/ph13060116. PMC 7345023. PMID 32512768.
Wilkes S (2008). "The use of bupropion SR in cigarette smoking cessation". International Journal of Chronic Obstructive Pulmonary Disease. 3 (1): 45–53. doi:10.2147/copd.s1121. PMC 2528204. PMID 18488428.
Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, et al. (May 2023). "Antidepressants for smoking cessation". The Cochrane Database of Systematic Reviews. 2023 (5): CD000031. doi:10.1002/14651858.CD000031.pub6. PMC 10207863. PMID 37230961.{{cite journal}}: CS1 maint: article number as page number (link)
Wu P, Wilson K, Dimoulas P, Mills EJ (December 2006). "Effectiveness of smoking cessation therapies: a systematic review and meta-analysis". BMC Public Health. 6 300. doi:10.1186/1471-2458-6-300. PMC 1764891. PMID 17156479.
Mooney ME, Sofuoglu M (July 2006). "Bupropion for the treatment of nicotine withdrawal and craving". Expert Review of Neurotherapeutics. 6 (7): 965–981. doi:10.1586/14737175.6.7.965. PMID 16831112. S2CID 19195413.
Rosen LJ, Galili T, Kott J, Goodman M, Freedman LS (May 2018). "Diminishing benefit of smoking cessation medications during the first year: a meta-analysis of randomized controlled trials". Addiction. 113 (5): 805–816. doi:10.1111/add.14134. PMC 5947828. PMID 29377409.
Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Chubb E, et al. (October 2019). "Relapse prevention interventions for smoking cessation". The Cochrane Database of Systematic Reviews. 2019 (10). doi:10.1002/14651858.CD003999.pub6. PMC 6816175. PMID 31684681.
Patnode CD, Henderson JT, Coppola EL, Melnikow J, Durbin S, Thomas RG (January 2021). "Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 325 (3): 280–298. doi:10.1001/jama.2020.23541. PMID 33464342.
Selph S, Patnode C, Bailey SR, Pappas M, Stoner R, Chou R (April 2020). "Primary Care-Relevant Interventions for Tobacco and Nicotine Use Prevention and Cessation in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 323 (16): 1599–1608. doi:10.1001/jama.2020.3332. PMID 32343335.
Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J, et al. (March 2020). "Pharmacological interventions for promoting smoking cessation during pregnancy". The Cochrane Database of Systematic Reviews. 2020 (3): CD010078. doi:10.1002/14651858.CD010078.pub3. PMC 7059898. PMID 32129504.{{cite journal}}: CS1 maint: article number as page number (link)
Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. (October 2019). "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Pediatrics. 144 (4) e20192528. doi:10.1542/peds.2019-2528. PMC 7067282. PMID 31570648.
Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, et al. (2020). "Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis". PLOS ONE. 15 (10): e0240584. Bibcode:2020PLoSO..1540584E. doi:10.1371/journal.pone.0240584. PMC 7577505. PMID 33085721.{{cite journal}}: CS1 maint: article number as page number (link)
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. (September 2018). "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis". The Lancet. Psychiatry. 5 (9): 727–738. doi:10.1016/S2215-0366(18)30269-4. PMC 6109107. PMID 30097390.
Ng QX (March 2017). "A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Journal of Child and Adolescent Psychopharmacology. 27 (2): 112–116. doi:10.1089/cap.2016.0124. PMID 27813651.
Wilens TE, Morrison NR, Prince J (October 2011). "An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults". Expert Review of Neurotherapeutics. 11 (10): 1443–1465. doi:10.1586/ern.11.137. PMC 3229037. PMID 21955201.
Serretti A, Chiesa A (June 2009). "Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis". Journal of Clinical Psychopharmacology. 29 (3): 259–266. doi:10.1097/JCP.0b013e3181a5233f. PMID 19440080. S2CID 1663570.
Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S (2004). "A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor". Primary Care Companion to the Journal of Clinical Psychiatry. 6 (4): 159–166. doi:10.4088/PCC.v06n0403. PMC 514842. PMID 15361919.
Basson R, Gilks T (2018). "Women's sexual dysfunction associated with psychiatric disorders and their treatment". Women's Health. 14 1745506518762664. doi:10.1177/1745506518762664. PMC 5900810. PMID 29649948.
Clayton AH, Kingsberg SA, Goldstein I (June 2018). "Evaluation and Management of Hypoactive Sexual Desire Disorder". Sexual Medicine. 6 (2): 59–74. doi:10.1016/j.esxm.2018.01.004. PMC 5960024. PMID 29523488.
Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, et al. (January 2017). "Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review". Mayo Clinic Proceedings. 92 (1): 114–128. doi:10.1016/j.mayocp.2016.09.018. PMID 27916394.
Razali NA, Sidi H, Choy CL, Ross NA, Baharudin A, Das S (February 2022). "The Role of Bupropion in the Treatment of Women with Sexual Desire Disorder: A Systematic Review and Meta-Analysis". Curr Neuropharmacol. 20 (10): 1941–1955. doi:10.2174/1570159X20666220222145735. PMC 9886814. PMID 35193485. S2CID 247057961.
Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. (April 2005). "Meta-analysis: pharmacologic treatment of obesity". Annals of Internal Medicine. 142 (7): 532–546. doi:10.7326/0003-4819-142-7-200504050-00012. PMID 15809465.
Kampman KM (June 2008). "The search for medications to treat stimulant dependence". Addiction Science & Clinical Practice. 4 (2): 28–35. doi:10.1151/ascp084228 (inactive 11 July 2025). PMC 2797110. PMID 18497715.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
Cao DN, Shi JJ, Hao W, Wu N, Li J (June 2016). "Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction". European Journal of Pharmacology. 780: 129–135. doi:10.1016/j.ejphar.2016.03.040. PMID 27018393.
Akbar D, Rhee TG, Ceban F, Ho R, Teopiz KM, Cao B, et al. (October 2023). "Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials". CNS Drugs. 37 (10): 867–881. doi:10.1007/s40263-023-01032-5. PMID 37792265.
Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ (September 2006). "Antidepressants and inflammatory bowel disease: a systematic review". Clinical Practice and Epidemiology in Mental Health. 2: 24. doi:10.1186/1745-0179-2-24. PMC 1599716. PMID 16984660.
Thorkelson G, Bielefeldt K, Szigethy E (June 2016). "Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD". Inflammatory Bowel Diseases. 22 (6): 1509–1522. doi:10.1097/MIB.0000000000000734. PMID 27167571.
Eskeland S, Halvorsen JA, Tanum L (August 2017). "Antidepressants have Anti-inflammatory Effects that may be Relevant to Dermatology: A Systematic Review". Acta Dermato-Venereologica. 97 (8): 897–905. doi:10.2340/00015555-2702. hdl:10852/63759. PMID 28512664.
Ferraro MC, Urquhart DM, Ferreira GE, Wewege MA, Abdel Shaheed C, Traeger AC, et al. (2025). "Antidepressants for low back pain and spine-related leg pain". The Cochrane Database of Systematic Reviews. 2025 (3): CD001703. doi:10.1002/14651858.CD001703.pub4. PMC 11890917. PMID 40058767.{{cite journal}}: CS1 maint: article number as page number (link)
Ono T, Takenoshita S, Nishino S (September 2022). "Pharmacologic Management of Excessive Daytime Sleepiness". Sleep Med Clin. 17 (3): 485–503. doi:10.1016/j.jsmc.2022.06.012. PMID 36150809.
Nishino S, Kotorii N (2016). "Overview of Management of Narcolepsy". Narcolepsy. Cham: Springer International Publishing. pp. 285–305. doi:10.1007/978-3-319-23739-8_21. ISBN 978-3-319-23738-1.
Rye DB, Dihenia B, Bliwise DL (1998). "Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion". Depress Anxiety. 7 (2): 92–95. doi:10.1002/(SICI)1520-6394(1998)7:2<92::AID-DA9>3.0.CO;2-7. PMID 9614600.
Goksan B, Mercan S, Karamustafalioglu O (2005). "Bupropion is effective in depression in narcolepsy". Int J Psychiatry Clin Pract. 9 (4): 289–291. doi:10.1080/13651500500241454. PMID 24930928.
Hailwood JM (27 September 2018). Novel approaches towards pharmacological enhancement of motivation (Thesis). University of Cambridge. pp. 13–14. doi:10.17863/CAM.40216. Bupropion also acts as a dopamine reuptake inhibitor (Dwoskin et al. 2006), and has been used as a treatment for depression as well as a smoking cessation aid (Stahl et al. 2004). Bupropion has been shown to produce a dose-dependent increase in PR breakpoints (Bruijnzeel & Markou 2003). Furthermore, systemic administration of bupropion increases the selection of the high-effort, high-reward option in a PR-choice task in rats (Randall, Lee, Podurgiel, et al. 2014). Bupropion is also effective at rescuing motivational impairments in rodents. Administration of bupropion can rescue deficits in effort-related decision-making induced by pre-treatment with tetrabenazine (Randall, Lee, Nunes, et al. 2014; Nunes, Randall, Hart, et al. 2013) and the pro-inflammatory cytokine interleukin-6 (Yohn, Arif, et al. 2016). Bupropion has been reported to improve symptoms of apathy in cases of acquired brain injury, major depression (Corcoran et al. 2004), and frontotemporal dementia (Lin et al. 2016). | However, several larger placebo-controlled studies suggest only limited effects of bupropion. In a study of 40 patients with schizophrenia, bupropion was found to have no significant effect on apathy or negative symptoms as a whole (Yassini et al. 2014). Furthermore, in a recent RCT of bupropion in HD, apathy was not significantly affected by the drug (Gelderblom et al. 2017). | It is not clear whether bupropion lacks clinical efficacy, whether bupropion as a whole is not effective at treating motivational impairments, or is not effective in the clinical populations tested.
Marin RS, Wilkosz PA (2005). "Disorders of diminished motivation". J Head Trauma Rehabil. 20 (4): 377–88. doi:10.1097/00001199-200507000-00009. PMID 16030444.
Lyonga Ngonge A, Nyange C, Ghali JK (February 2024). "Novel pharmacotherapeutic options for the treatment of postural orthostatic tachycardia syndrome". Expert Opin Pharmacother. 25 (2): 181–188. doi:10.1080/14656566.2024.2319224. PMID 38465412.
Vyas R, Nesheiwat Z, Ruzieh M, Ammari Z, Al-Sarie M, Grubb B (August 2020). "Bupropion in the treatment of postural orthostatic tachycardia syndrome (POTS): a single-center experience". J Investig Med. 68 (6): 1156–1158. doi:10.1136/jim-2020-001272. PMID 32606041.
Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. (March 2021). "Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials". Expert Opinion on Emerging Drugs. 26 (1): 63–74. doi:10.1080/14728214.2021.1898588. PMID 33682569. S2CID 232141396.
Alberti S, Chiesa A, Andrisano C, Serretti A (June 2015). "Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis". Journal of Clinical Psychopharmacology. 35 (3): 296–303. doi:10.1097/JCP.0000000000000329. PMID 25874915. S2CID 33102792. Archived from the original on 8 March 2023. Retrieved 13 November 2022.
Telang S, Walton C, Olten B, Bloch MH (August 2018). "Meta-analysis: Second generation antidepressants and headache". Journal of Affective Disorders. 236: 60–68. doi:10.1016/j.jad.2018.04.047. PMID 29715610. S2CID 19196303.
Kittle J, Lopes RD, Huang M, Marquess ML, Wilson MD, Ascher J, et al. (October 2017). "Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort". Clinical Cardiology. 40 (10): 899–906. doi:10.1002/clc.22744. PMC 6490529. PMID 28605035.
Grandi SM, Shimony A, Eisenberg MJ (December 2013). "Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials". The Canadian Journal of Cardiology. 29 (12): 1704–1711. doi:10.1016/j.cjca.2013.09.014. PMID 24267809.
Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R (2002). "Effects of psychotropic drugs on seizure threshold". Drug Safety. 25 (2): 91–110. doi:10.2165/00002018-200225020-00004. PMID 11888352. S2CID 25290793.
Wu A, Khawaja AP, Pasquale LR, Stein JD (January 2020). "A review of systemic medications that may modulate the risk of glaucoma". Eye. 34 (1): 12–28. doi:10.1038/s41433-019-0603-z. PMC 7002596. PMID 31595027.
Herstowska M, Komorowska O, Cubała WJ, Jakuszkowiak-Wojten K, Gałuszko-Węgielnik M, Landowski J (May 2014). "Severe skin complications in patients treated with antidepressants: a literature review". Postepy Dermatologii I Alergologii. 31 (2): 92–97. doi:10.5114/pdia.2014.40930. PMC 4112250. PMID 25097474.
Goodnick PJ, Jerry J, Parra F (May 2002). "Psychotropic drugs and the ECG: focus on the QTc interval". Expert Opin Pharmacother. 3 (5): 479–498. doi:10.1517/14656566.3.5.479. PMID 11996627.
Jasiak NM, Bostwick JR (December 2014). "Risk of QT/QTc prolongation among newer non-SSRI antidepressants". Ann Pharmacother. 48 (12): 1620–1628. doi:10.1177/1060028014550645. PMID 25204465.
Caillier B, Pilote S, Castonguay A, Patoine D, Ménard-Desrosiers V, Vigneault P, et al. (October 2012). "QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile". Fundam Clin Pharmacol. 26 (5): 599–608. doi:10.1111/j.1472-8206.2011.00953.x. PMID 21623902.
Henssler J, Heinz A, Brandt L, Bschor T (May 2019). "Antidepressant Withdrawal and Rebound Phenomena". Deutsches Ärzteblatt International. 116 (20): 355–361. doi:10.3238/arztebl.2019.0355. PMC 6637660. PMID 31288917.
White N, Litovitz T, Clancy C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type". Journal of Medical Toxicology. 4 (4): 238–250. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
Jefferson JW, Pradko JF, Muir KT (November 2005). "Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations". Clinical Therapeutics. 27 (11): 1685–1695. doi:10.1016/j.clinthera.2005.11.011. PMID 16368442.
Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS, et al. (October 1995). "Carbamazepine but not valproate induces bupropion metabolism". Journal of Clinical Psychopharmacology. 15 (5): 327–333. doi:10.1097/00004714-199510000-00004. PMID 8830063.
Todor I, Popa A, Neag M, Muntean D, Bocsan C, Buzoianu A, et al. (2016). "Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers". Journal of Pharmacy & Pharmaceutical Sciences. 19 (2): 198–207. doi:10.18433/J3H03R. PMID 27518170.
Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, et al. (April 2015). "Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects". The Journal of Pharmacology and Experimental Therapeutics. 353 (1): 102–111. doi:10.1124/jpet.114.222356. PMID 25655950. S2CID 14761997.
Protti M, Mandrioli R, Marasca C, Cavalli A, Serretti A, Mercolini L (September 2020). "New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others". Medicinal Research Reviews. 40 (5): 1794–1832. doi:10.1002/med.21671. hdl:11585/762375. PMID 32285503. S2CID 215758102.
Spina E, Santoro V, D'Arrigo C (July 2008). "Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update". Clinical Therapeutics. 30 (7): 1206–1227. doi:10.1016/s0149-2918(08)80047-1. PMID 18691982.
Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008). "Pharmacotherapy of methamphetamine addiction: an update". Subst Abus. 29 (3): 31–49. Bibcode:2008JPkR...29...31E. doi:10.1080/08897070802218554. PMC 2597382. PMID 19042205.
Simmler LD, Wandeler R, Liechti ME (June 2013). "Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence". BMC Res Notes. 6 220. doi:10.1186/1756-0500-6-220. PMC 3679734. PMID 23734766.
Newton TF, Roache JD, De La Garza R, Fong T, Wallace CL, Li SH, et al. (July 2006). "Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving". Neuropsychopharmacology. 31 (7): 1537–1544. doi:10.1038/sj.npp.1300979. PMID 16319910.
Feinberg SS (November 2004). "Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication". The Journal of Clinical Psychiatry. 65 (11): 1520–1524. doi:10.4088/jcp.v65n1113. PMID 15554766.
Richelson E, Nelson A (July 1984). "Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro". J Pharmacol Exp Ther. 230 (1): 94–102. doi:10.1016/S0022-3565(25)21446-X. PMID 6086881.
Wander TJ, Nelson A, Okazaki H, Richelson E (December 1986). "Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro". Eur J Pharmacol. 132 (2–3): 115–121. doi:10.1016/0014-2999(86)90596-0. PMID 3816971.
Cusack B, Nelson A, Richelson E (May 1994). "Binding of antidepressants to human brain receptors: focus on newer generation compounds". Psychopharmacology (Berl). 114 (4): 559–565. doi:10.1007/BF02244985. PMID 7855217.
Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur J Pharmacol. 340 (2–3): 249–258. doi:10.1016/s0014-2999(97)01393-9. PMID 9537821.
Sánchez C, Hyttel J (August 1999). "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". Cell Mol Neurobiol. 19 (4): 467–489. doi:10.1023/a:1006986824213. PMC 11545528. PMID 10379421.
Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, et al. (September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors". Mol Pharmacol. 66 (3): 675–682. doi:10.1124/mol.104.001313. PMID 15322260.
Shalabi AR, Walther D, Baumann MH, Glennon RA (June 2017). "Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release". ACS Chemical Neuroscience. 8 (6): 1397–1403. doi:10.1021/acschemneuro.7b00055. PMC 7261150. PMID 28220701.
Hart XM, Spangemacher M, Defert J, Uchida H, Gründer G (April 2024). "Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants". Ther Drug Monit. 46 (2): 155–169. doi:10.1097/FTD.0000000000001142. PMID 38287888.
Egerton A, Shotbolt JP, Stokes PR, Hirani E, Ahmad R, Lappin JM, et al. (March 2010). "Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study". NeuroImage. 50 (1): 260–266. doi:10.1016/j.neuroimage.2009.11.077. PMC 4135078. PMID 19969097.
Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, et al. (November 2005). "Bupropion increases striatal vesicular monoamine transport". Neuropharmacology. New Perspectives in Neurotransmitter Transporter Biology. 49 (6): 820–830. doi:10.1016/j.neuropharm.2005.05.004. PMID 16005476. S2CID 26035635.
Lukas RJ, Muresan AZ, Damaj MI, Blough BE, Huang X, Navarro HA, et al. (June 2010). "Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation". Journal of Medicinal Chemistry. 53 (12): 4731–4748. doi:10.1021/jm1003232. PMC 2895766. PMID 20509659.
Andersen J, Ringsted KB, Bang-Andersen B, Strømgaard K, Kristensen AS (27 October 2015). "Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter". Scientific Reports. 5 (1) 15650. Bibcode:2015NatSR...515650A. doi:10.1038/srep15650. ISSN 2045-2322. PMC 4621520. PMID 26503701.
Sałaciak K, Pytka K (January 2022). "Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders". Neurosci Biobehav Rev. 132: 1114–1136. doi:10.1016/j.neubiorev.2021.10.037. PMC 8559442. PMID 34736882.
Dhir A, Kulkarni SK (August 2008). "Possible involvement of sigma-1 receptors in the anti-immobility action of bupropion, a dopamine reuptake inhibitor". Fundam Clin Pharmacol. 22 (4): 387–394. doi:10.1111/j.1472-8206.2008.00605.x. PMID 18705749.
Brimson JM, Brimson S, Chomchoei C, Tencomnao T (October 2020). "Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain". Expert Opin Ther Targets. 24 (10): 1009–1028. doi:10.1080/14728222.2020.1805435. PMID 32746649. AXS-05 is a combination of dextromethorphan and bupropion and has been shown to have a rapid (within one week) positive effect in patients with depression. Dextromethorphan, as described above as part of Nuedexta, is a σ-1R agonist, an NMDA antagonist, and has an affinity for the serotonin reuptake transporter. Whereas, bupropion is a moderately effective antidepressant when taken alone, thought to act by preventing dopamine and noradrenaline reuptake [230]. Studies in mice have shown that the antidepressant-like effects of bupropion are potentiated by σ-1R agonists, and inhibited by σ-1R antagonists [231]. These findings suggest that the combination of a σ-1R agonist and the dopamine/ noradrenaline reuptake inhibitor will be more effective than either treatment alone.
Ferris RM, Russell A, Tang FL, Topham PA (1991). "Labeling in vivo of sigma receptors in mouse brain with [ 3 H]-(+)-SKF 10,047: Effects of phencyclidine, (+)- and (−)-N-allylnormetazocine, and other drugs". Drug Development Research. 24 (1): 81–92. doi:10.1002/ddr.430240107. ISSN 0272-4391.
Pei Y, Asif-Malik A, Canales JJ (2016). "Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications". Front Neurosci. 10: 148. doi:10.3389/fnins.2016.00148. PMC 4820462. PMID 27092049.
Docherty JR, Alsufyani HA (August 2021). "Pharmacology of Drugs Used as Stimulants". J Clin Pharmacol. 61 (Suppl 2): S53 – S69. doi:10.1002/jcph.1918. PMID 34396557. Many stimulants have potency at the rat TAAR1 in the micromolar range but tend to be about 5 to 10 times less potent at the human TAAR1, but bupropion was found to be inactive.87,88
Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1" (PDF). J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID 26791601. Archived from the original (PDF) on 9 May 2025.
Gursahani H, Jolas T, Martin M, Cotier S, Hughes S, Macfadden W, et al. (2023). "Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion". CNS Spectrums. 28 (2): 222. doi:10.1017/S1092852923001396. ISSN 1092-8529. In vitro functional studies showed agonist activity of solriamfetol at human, mouse, and rat TAAR1 receptors. hTAAR1 EC50 values (10–16 μM) were within the clinically observed therapeutic solriamfetol plasma concentration range and overlapped with the observed DAT/NET inhibitory potencies of solriamfetol in vitro. TAAR1 agonist activity was unique to solriamfetol; neither the WPA modafinil nor the DAT/NET inhibitor bupropion had TAAR1 agonist activity.
Wainscott DB, Little SP, Yin T, Tu Y, Rocco VP, He JX, et al. (January 2007). "Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1". J Pharmacol Exp Ther. 320 (1): 475–485. doi:10.1124/jpet.106.112532. PMID 17038507.
Strawbridge R, Izurieta E, Day E, Tee H, Young K, Tong CC, et al. (2023). "Peripheral inflammatory effects of different interventions for treatment-resistant depression: A systematic review". Neuroscience Applied. 2 101014. Elsevier BV. doi:10.1016/j.nsa.2022.101014. ISSN 2772-4085. PMC 12244173. PMID 40655965. S2CID 253283525.
Karimollah A, Hemmatpur A, Vahid T (August 2021). "Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3". Inflammopharmacology. 29 (4): 1101–1109. doi:10.1007/s10787-021-00829-4. PMID 34218389. S2CID 234883621.
Yetkin D, Yılmaz İA, Ayaz F (September 2023). "Anti-inflammatory activity of bupropion through immunomodulation of the macrophages". Naunyn-Schmiedeberg's Arch Pharmacol. 396 (9): 2087–2093. doi:10.1007/s00210-023-02462-0. PMID 36928557. S2CID 257583439.
Chen WC, Lai HC, Su WP, Palani M, Su KP (January 2015). "Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: an open-label study". Psychiatry Investig. 12 (1): 142–5. doi:10.4306/pi.2015.12.1.142. PMC 4310912. PMID 25670957.
Cámara-Lemarroy CR, Guzmán-de la Garza FJ, Cordero-Pérez P, Alarcón-Galván G, Ibarra-Hernández JM, Muñoz-Espinosa LE, et al. (2013). "Bupropion reduces the inflammatory response and intestinal injury due to ischemia-reperfusion". Transplant Proc. 45 (6): 2502–5. doi:10.1016/j.transproceed.2013.04.010. PMID 23953570.
Tafseer S, Gupta R, Ahmad R, Jain S, Bhatia MS, Gupta LK (January 2021). "Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder". Pharmacol Biochem Behav. 200 173073. doi:10.1016/j.pbb.2020.173073. PMID 33186562. S2CID 226292409.
Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB (June 2006). "A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice". Int Immunopharmacol. 6 (6): 903–7. doi:10.1016/j.intimp.2005.12.007. PMID 16644475. Archived from the original on 16 October 2023. Retrieved 25 October 2023.
Kharasch ED, Neiner A, Kraus K, Blood J, Stevens A, Schweiger J, et al. (May 2019). "Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial". Clinical Pharmacology and Therapeutics. 105 (5): 1164–1174. doi:10.1002/cpt.1309. PMC 6465131. PMID 30460996.
Kharasch ED, Neiner A, Kraus K, Blood J, Stevens A, Miller JP, et al. (November 2020). "Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults". Clinical Pharmacology and Therapeutics. 108 (5): 1036–1048. doi:10.1002/cpt.1888. PMID 32386065. S2CID 218563059.
Sánchez C, Hyttel J (August 1999). "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". Cellular and Molecular Neurobiology. 19 (4): 467–489. doi:10.1023/a:1006986824213. PMC 11545528. PMID 10379421. S2CID 19490821.
Bondarev ML, Bondareva TS, Young R, Glennon RA (August 2003). "Behavioral and biochemical investigations of bupropion metabolites". European Journal of Pharmacology. 474 (1): 85–93. doi:10.1016/S0014-2999(03)02010-7. PMID 12909199.
Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, et al. (September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors". Molecular Pharmacology. 66 (3): 675–682. doi:10.1124/mol.104.001313. PMID 15322260. S2CID 1577336.
Stuebler AG, Jansen M (March 2020). "Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations". Molecular Pharmacology. 97 (3): 171–179. doi:10.1124/mol.119.118349. PMC 6978693. PMID 31871303.
Pandhare A, Pappu AS, Wilms H, Blanton MP, Jansen M (February 2017). "The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors". Neuropharmacology. 113 (Pt A): 89–99. doi:10.1016/j.neuropharm.2016.09.021. PMC 5148637. PMID 27671323.
Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, et al. (April 2004). "Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes". Pharmacogenetics. 14 (4): 225–238. doi:10.1097/00008571-200404000-00002. PMID 15083067.
Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI (2014). "Bupropion and bupropion analogs as treatments for CNS disorders". Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Adv Pharmacol. Vol. 69. pp. 177–216. doi:10.1016/B978-0-12-420118-7.00005-6. ISBN 978-0-12-420118-7. PMID 24484978.
Costa R, Oliveira NG, Dinis-Oliveira RJ (August 2019). "Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects". Drug Metab Rev. 51 (3): 293–313. doi:10.1080/03602532.2019.1620763. PMID 31124380.
Welch RM, Lai AA, Schroeder DH (March 1987). "Pharmacological significance of the species differences in bupropion metabolism". Xenobiotica. 17 (3): 287–298. doi:10.3109/00498258709043939. PMID 3107223.
Naglich AC, Brown ES, Adinoff B (2019). "Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential". Am J Drug Alcohol Abuse. 45 (4): 341–354. doi:10.1080/00952990.2018.1545023. PMID 30601027.
Musso DL, Mehta NB, Soroko FE, Ferris RM, Hollingsworth EB, Kenney BT (1993). "Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion". Chirality. 5 (7): 495–500. doi:10.1002/chir.530050704. PMID 8240925.
Glennon RA (2014). "Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention". Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Adv Pharmacol. Vol. 69. pp. 581–620. doi:10.1016/B978-0-12-420118-7.00015-9. ISBN 978-0-12-420118-7. PMC 4471862. PMID 24484988. Bupropion, the N-tert-butyl analog of 3-chlorocathinone, is a clinically employed antidepressant.
Shalabi AR, Walther D, Baumann MH, Glennon RA (June 2017). "Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release". ACS Chem Neurosci. 8 (6): 1397–1403. doi:10.1021/acschemneuro.7b00055. PMC 7261150. PMID 28220701.
Shalabi AR (14 December 2017). Structure-Activity Relationship Studies of Bupropion and Related 3-Substituted Methcathinone Analogues at Monoamine Transporters. VCU Scholars Compass (Thesis). doi:10.25772/M4E1-3549. Retrieved 24 November 2024.
Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA (April 2021). "Designer drugs: a medicinal chemistry perspective (II)". Ann N Y Acad Sci. 1489 (1): 48–77. Bibcode:2021NYASA1489...48C. doi:10.1111/nyas.14349. PMID 32396701.
Mazzoni I, Rabin O (2024). "NPS, PEDs and other emerging drugs on the Clearnet and the Darkweb: Use in sport". Emerging Trends in Drugs, Addictions, and Health. 4 100148. doi:10.1016/j.etdah.2024.100148.
Carroll FI, Blough BE, Abraham P, Mills AC, Holleman JA, Wolckenhauer SA, et al. (November 2009). "Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction". J Med Chem. 52 (21): 6768–6781. doi:10.1021/jm901189z. PMID 19821577.
Blough BE, Landavazo A, Partilla JS, Baumann MH, Decker AM, Page KM, et al. (June 2014). "Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics". ACS Med Chem Lett. 5 (6): 623–627. doi:10.1021/ml500113s. PMC 4060932. PMID 24944732.
Weintraub D, Linder MW (2000). "Amphetamine positive toxicology screen secondary to bupropion". Depression and Anxiety. 12 (1): 53–54. doi:10.1002/1520-6394(2000)12:1<53::AID-DA8>3.0.CO;2-4. PMID 10999247. S2CID 43480769.
Nixon AL, Long WH, Puopolo PR, Flood JG (June 1995). "Bupropion metabolites produce false-positive urine amphetamine results". Clinical Chemistry. 41 (6 Pt 1): 955–956. doi:10.1093/clinchem/41.6.955. PMID 7768026.
Casey ER, Scott MG, Tang S, Mullins ME (June 2011). "Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay". Journal of Medical Toxicology. 7 (2): 105–108. doi:10.1007/s13181-010-0131-5. PMC 3724447. PMID 21191682.
Perrine DM, Ross JT, Nervi SJ, Zimmerman RH (2000). "A Short, One-Pot Synthesis of Bupropion (Zyban, Wellbutrin)". Journal of Chemical Education. 77 (11): 1479. Bibcode:2000JChEd..77.1479P. doi:10.1021/ed077p1479.
Naglich AC, Brown ES, Adinoff B (2019). "Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential". The American Journal of Drug and Alcohol Abuse. 45 (4): 341–354. doi:10.1080/00952990.2018.1545023. PMID 30601027. S2CID 58587857.
Lile JA, Nader MA (2003). "The abuse liability and therapeutic potential of drugs evaluated for cocaine addiction as predicted by animal models". Current Neuropharmacology. 1: 21–46. CiteSeerX 10.1.1.325.9635. doi:10.2174/1570159033360566.
Phillips D (February 2012). "Wellbutrin®: misuse and abuse by incarcerated individuals". Journal of Addictions Nursing. 23 (1): 65–69. doi:10.3109/10884602.2011.647838. PMID 22468662. S2CID 1310940.
Baribeau D, Araki KF (May–June 2013). "Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent". Journal of Addiction Medicine. 7 (3): 216–217. doi:10.1097/ADM.0b013e3182824863. PMID 23519045.
Stassinos GL, Klein-Schwartz W (2016). "Bupropion "Abuse" Reported to US Poison Centers". Journal of Addiction Medicine. 10 (5): 357–362. doi:10.1097/ADM.0000000000000249. PMID 27504927. S2CID 24870292.
Schneier FR (March 2011). "Pharmacotherapy of social anxiety disorder". Expert Opin Pharmacother. 12 (4): 615–625. doi:10.1517/14656566.2011.534983. PMID 21241211.
Emmanuel NP, Lydiard RB, Ballenger JC (August 1991). "Treatment of social phobia with bupropion". J Clin Psychopharmacol. 11 (4): 276–277. doi:10.1097/00004714-199108000-00023. PMID 1918431.
Emmanuel NP, Brawman-Mintzer O, Morton WA, Book SW, Johnson MR, Lorberbaum JP, et al. (2000). "Bupropion-SR in treatment of social phobia". Depress Anxiety. 12 (2): 111–113. doi:10.1002/1520-6394(2000)12:2<111::AID-DA9>3.0.CO;2-3. PMID 11091936.

drugabuse.gov (Global: 6,166^th place; English: 5,476^th place)

Whitten L (April 2006). "Bupropion helps people with schizophrenia quit smoking". National Institute on Drug Abuse Research Findings. 20 (5). Archived from the original on 5 August 2007. Retrieved 27 May 2013.

drugbank.com (Global: low place; English: low place)

go.drugbank.com

"Bupropion: Uses, Interactions, Mechanism of Action". DrugBank Online. 30 March 2009. Retrieved 4 August 2024.

drugs.com (Global: 399^th place; English: 333^rd place)

"Bupropion Use During Pregnancy". Drugs.com. Archived from the original on 24 December 2018. Retrieved 24 December 2018.

emedexpert.com (Global: low place; English: low place)

"Bupropion (Wellbutrin)". eMedExpert.com. 31 March 2008. Archived from the original on 6 August 2013. Retrieved 20 August 2013.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Bupropion hydrochloride EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 18 August 2022. Retrieved 7 March 2023.
Committee for Medicinal Products for Human Use (CHMP) (24 March 2017). "EMA recommends suspension of medicines due to unreliable studies from Micro Therapeutic Research Labs". European Medicines Agency. Archived from the original on 26 October 2020. Retrieved 26 November 2020.
Committee for Medicinal Products for Human Use (CHMP) (23 March 2017). "Products for which the marketing authorisations are recommended for suspension and marketing authorisation applications which do not satisfy the criteria for authorisation as adopted by the CHMP" (PDF). European Medicines Agency. Archived (PDF) from the original on 19 January 2021. Retrieved 26 November 2020.
"EMA advises companies on steps to take avoid nitrosamines in human medicines". European Medicines Agency (EMA). 26 September 2019. Archived from the original on 11 November 2023. Retrieved 24 October 2023.

exlibrisgroup.com (Global: 9,042^nd place; English: 5,814^th place)

unisa.alma.exlibrisgroup.com

De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E (March 2021). "A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants". Drug Safety. 44 (3): 291–312. doi:10.1007/s40264-020-01027-x. PMID 33354752. S2CID 229357583. Archived from the original on 7 March 2023. Retrieved 17 May 2022.

fda.gov (Global: 447^th place; English: 338^th place)

accessdata.fda.gov

"Wellbutrin approval package" (PDF). U.S. Food and Drug Administration (FDA). 30 December 1985. Archived from the original (PDF) on 27 November 2020. Retrieved 5 May 2020.
"Drug Approval Package: Contrave (naltrexone hydrochloride/bupropion hydrochloride) Extended-Release Tablets NDA #200063". U.S. Food and Drug Administration (FDA). Archived from the original on 4 June 2020. Retrieved 5 May 2020.
"Highlight os Prescribing Information: CONTRAVE (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets, for oral use" (PDF). Currax Pharmaceuticals LLC. U.S. Food and Drug Administration. August 2020. Archived (PDF) from the original on 19 October 2020. Retrieved 1 December 2020.
"Wellbutrin entry in the Orange Book". U.S. Food and Drug Administration Center for Drug Evaluation and Research. Archived from the original on 25 February 2011. Retrieved 18 August 2007.
"Drug Approval Package: Wellbutrin XL (Bupropion HCI) NDA #021515". U.S. Food and Drug Administration (FDA). 22 April 2005. Archived from the original on 5 December 2019. Retrieved 4 December 2019.
"Drug Approval Package: Zyban NDA# 020711". U.S. Food and Drug Administration (FDA). 8 August 2003. Archived from the original on 5 December 2019. Retrieved 4 December 2019.
"FDA approval letter" (PDF). U.S. Food and Drug Administration (FDA). 6 December 2006. Archived (PDF) from the original on 1 November 2020. Retrieved 21 October 2020.
"Drug Approval Package: Aplenzin (Bupropion Hydrobromide) NDA 22108". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 15 August 2020. Retrieved 5 May 2020.
Center for Drug Evaluation and Research. "Application number 22-108 Cross Discipline Team Leader Review" (PDF). accessdata.fda.gov. Archived from the original (PDF) on 28 February 2017.

fda.gov

Levenson M, Holland C. "Antidepressants and suicidality in adults: statistical evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; December 13, 2006)". U.S. Food and Drug Administration (FDA). Archived from the original on 27 September 2007. Retrieved 13 May 2007.
"Review of therapeutic equivalence: generic bupropion XL 300 mg and Wellbutrin XL 300 mg". Food and Drug Administration. Archived from the original on 6 June 2011. Retrieved 19 April 2008.
"Budeprion XL 300 mg not therapeutically equivalent to Wellbutrin XL 300 mg". U.S. Food and Drug Administration (FDA). 3 October 2012. Archived from the original on 13 December 2019. Retrieved 23 March 2013. This article incorporates text from this source, which is in the public domain.
"Public Health Advisory: FDA requires new boxed warnings for the smoking cessation drugs Chantix and Zyban". U.S. Food and Drug Administration (FDA). 1 July 2009. Archived from the original on 19 October 2010. Retrieved 3 July 2009.
"The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics) suicidal ideation and behavior" (PDF). Drug Safety Newsletter. 2 (1): 1–4. 2009. Archived from the original (PDF) on 11 February 2017. Retrieved 16 December 2019.
"Safety Alerts for Human Medical Products – Chantix (varenicline) and Zyban (bupropion)". Drug Safety Communication – Mental Health Side Effects Revised. U.S. Food and Drug Administration (FDA). 16 December 2016. Archived from the original on 20 December 2016. Retrieved 20 December 2016.

fiocruz.br (Global: low place; English: low place)

arca.fiocruz.br

Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB (June 2006). "A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice". Int Immunopharmacol. 6 (6): 903–7. doi:10.1016/j.intimp.2005.12.007. PMID 16644475. Archived from the original on 16 October 2023. Retrieved 25 October 2023.

garant.ru (Global: 1,937^th place; English: 7,777^th place)

base.garant.ru

"Постановление Правительства РФ от 30 июня 1998 г. N 681 "Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации" (с изменениями и дополнениями) Resolution of the Government of the Russian Federation of June 30, 1998 N 681 "On approval of the list of narcotic drugs, psychotropic substances and their precursors subject to control in the Russian Federation" (with amendments and additions)". base.garant.ru (in Russian). Гарант Garant (reference and legal system). 30 June 1998. Archived from the original on 20 April 2013. Retrieved 28 April 2019. Эфедрон (меткатинон) и его производные, за исключением производных, включенных в качестве самостоятельных позиций в перечень Ephedrone (methcathinone) and its derivatives, with the exception of derivatives included as independent items in the list.

globalnews.ca (Global: 985^th place; English: 583^rd place)

Antidepressant Wellbutrin becomes 'poor man's cocaine' on Toronto streets Archived 26 October 2020 at the Wayback Machine Global News 18 September 2013.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN) : proposed international nonproprietary names : list 83". WHO Drug Information. 14 (2). hdl:10665/58135.
World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
Monden R, Roest AM, van Ravenzwaaij D, Wagenmakers EJ, Morey R, Wardenaar KJ, et al. (August 2018). "The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews" (PDF). Journal of Affective Disorders. 235: 393–398. doi:10.1016/j.jad.2018.04.040. hdl:11370/842b1441-d0f3-4797-b95b-3a6a72262150. PMID 29677603. S2CID 5011570. Archived (PDF) from the original on 27 February 2022. Retrieved 13 December 2021.
Eskeland S, Halvorsen JA, Tanum L (August 2017). "Antidepressants have Anti-inflammatory Effects that may be Relevant to Dermatology: A Systematic Review". Acta Dermato-Venereologica. 97 (8): 897–905. doi:10.2340/00015555-2702. hdl:10852/63759. PMID 28512664.
Protti M, Mandrioli R, Marasca C, Cavalli A, Serretti A, Mercolini L (September 2020). "New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others". Medicinal Research Reviews. 40 (5): 1794–1832. doi:10.1002/med.21671. hdl:11585/762375. PMID 32285503. S2CID 215758102.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Hengartner MP, Jakobsen JC, Sørensen A, Plöderl M (2020). "Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials". PLOS ONE. 15 (2): e0229381. Bibcode:2020PLoSO..1529381H. doi:10.1371/journal.pone.0229381. PMC 7043778. PMID 32101579.{{cite journal}}: CS1 maint: article number as page number (link)
Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, et al. (2020). "Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis". PLOS ONE. 15 (10): e0240584. Bibcode:2020PLoSO..1540584E. doi:10.1371/journal.pone.0240584. PMC 7577505. PMID 33085721.{{cite journal}}: CS1 maint: article number as page number (link)
Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008). "Pharmacotherapy of methamphetamine addiction: an update". Subst Abus. 29 (3): 31–49. Bibcode:2008JPkR...29...31E. doi:10.1080/08897070802218554. PMC 2597382. PMID 19042205.
Andersen J, Ringsted KB, Bang-Andersen B, Strømgaard K, Kristensen AS (27 October 2015). "Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter". Scientific Reports. 5 (1) 15650. Bibcode:2015NatSR...515650A. doi:10.1038/srep15650. ISSN 2045-2322. PMC 4621520. PMID 26503701.
Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA (April 2021). "Designer drugs: a medicinal chemistry perspective (II)". Ann N Y Acad Sci. 1489 (1): 48–77. Bibcode:2021NYASA1489...48C. doi:10.1111/nyas.14349. PMID 32396701.
Perrine DM, Ross JT, Nervi SJ, Zimmerman RH (2000). "A Short, One-Pot Synthesis of Bupropion (Zyban, Wellbutrin)". Journal of Chemical Education. 77 (11): 1479. Bibcode:2000JChEd..77.1479P. doi:10.1021/ed077p1479.

in.gov.br (Global: 3,151^st place; English: 5,932^nd place)

Brazilian Health Regulatory Agency (Anvisa) (31 March 2023). "RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 – Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 3 August 2023.

lww.com (Global: 2,769^th place; English: 3,314^th place)

journals.lww.com

Alberti S, Chiesa A, Andrisano C, Serretti A (June 2015). "Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis". Journal of Clinical Psychopharmacology. 35 (3): 296–303. doi:10.1097/JCP.0000000000000329. PMID 25874915. S2CID 33102792. Archived from the original on 8 March 2023. Retrieved 13 November 2022.

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

"Zyban 150 mg prolonged release tablets – Summary of Product Characteristics (SmPC)". (emc). 21 April 2022. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
"Zyban 150 mg prolonged release film-coated tablets – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 1 August 2013. Archived from the original on 20 July 2017. Retrieved 22 October 2013.

medscape.com (Global: 719^th place; English: 636^th place)

Waknine Y (8 May 2008). "FDA Approvals: Advair, Relistor, Aplenzin". Medscape. Archived from the original on 6 July 2022. Retrieved 9 May 2008.

mhmedical.com (Global: 6,846^th place; English: 4,957^th place)

accessmedicine.mhmedical.com

O'Donnell JM, Bies RR, Williams AJ (2023). "Chapter 18: Drug Therapy of Depression and Anxiety Disorders". In Brunton L, Knollman B (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics (14th ed.). New York: McGraw-Hill Education.

nbcnews.com (Global: 137^th place; English: 101^st place)

Stenson J (12 October 2007). "Report questions generic antidepressant". NBC News. Archived from the original on 11 October 2013. Retrieved 13 October 2007.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Costa R, Oliveira NG, Dinis-Oliveira RJ (August 2019). "Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects". Drug Metabolism Reviews. 51 (3): 293–313. doi:10.1080/03602532.2019.1620763. PMID 31124380. S2CID 163167323.
Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. (2005). "15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL". Primary Care Companion to the Journal of Clinical Psychiatry. 7 (3): 106–113. doi:10.4088/pcc.v07n0305. PMC 1163271. PMID 16027765.
Masters AR, Gufford BT, Lu JB, Metzger IF, Jones DR, Desta Z (August 2016). "Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers". The Journal of Pharmacology and Experimental Therapeutics. 358 (2): 230–238. doi:10.1124/jpet.116.232876. PMC 4959100. PMID 27255113.
Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK (April 2016). "Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant". Therapeutic Advances in Psychopharmacology. 6 (2): 99–144. doi:10.1177/2045125316629071. PMC 4837968. PMID 27141292.
Arandjelovic K, Eyre HA, Lavretsky H (October 2016). "Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports". The American Journal of Geriatric Psychiatry. 24 (10): 913–917. doi:10.1016/j.jagp.2016.05.010. PMC 5540329. PMID 27591914.
Dhillon S, Yang LP, Curran MP (2008). "Bupropion: a review of its use in the management of major depressive disorder". Drugs. 68 (5): 653–689. doi:10.2165/00003495-200868050-00011. PMID 18370448. S2CID 195687060.
Baldwin DS, Papakostas GI (2006). "Symptoms of fatigue and sleepiness in major depressive disorder". The Journal of Clinical Psychiatry. 67 (Suppl 6): 9–15. PMID 16848671.
Steinert T, Fröscher W (July 2018). "Epileptic Seizures Under Antidepressive Drug Treatment: Systematic Review". Pharmacopsychiatry. 51 (4): 121–135. doi:10.1055/s-0043-117962. PMID 28850959. S2CID 22436728.
Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, et al. (February 2005). "Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder". The Journal of Clinical Psychiatry. 66 (2): 253–259. doi:10.4088/jcp.v66n0215. PMID 15705013.
Voican CS, Corruble E, Naveau S, Perlemuter G (April 2014). "Antidepressant-induced liver injury: a review for clinicians". The American Journal of Psychiatry. 171 (4): 404–415. doi:10.1176/appi.ajp.2013.13050709. PMID 24362450.
Kumar S, Kodela S, Detweiler JG, Kim KY, Detweiler MB (November–December 2011). "Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature". General Hospital Psychiatry. 33 (6): 612–617. doi:10.1016/j.genhosppsych.2011.07.001. PMID 21872337.
Nelson JC, Spyker DA (May 2017). "Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000–2014". The American Journal of Psychiatry. 174 (5): 438–450. doi:10.1176/appi.ajp.2016.16050523. PMID 28135844.
De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E (March 2021). "A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants". Drug Safety. 44 (3): 291–312. doi:10.1007/s40264-020-01027-x. PMID 33354752. S2CID 229357583. Archived from the original on 7 March 2023. Retrieved 17 May 2022.
Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, et al. (October 2021). "Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants" (PDF). The World Journal of Biological Psychiatry. 22 (8): 561–628. doi:10.1080/15622975.2021.1878427. PMID 33977870. S2CID 234472488. Archived (PDF) from the original on 5 May 2022. Retrieved 10 April 2022.
Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI (2014). "Bupropion and bupropion analogs as treatments for CNS disorders". Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Advances in Pharmacology. Vol. 69. Academic Press. pp. 177–216. doi:10.1016/B978-0-12-420118-7.00005-6. ISBN 978-0-12-420118-7. PMID 24484978.
Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C (October 2017). "Bupropion for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2017 (10): CD009504. doi:10.1002/14651858.CD009504.pub2. PMC 6485546. PMID 28965364.{{cite journal}}: CS1 maint: article number as page number (link)
Gautam M, Patel S, Zarkowski P (January 2022). "Practice patterns of bupropion co-prescription with antipsychotic medications". J Addict Dis. 40 (4): 481–488. doi:10.1080/10550887.2022.2028531. PMID 35068363. S2CID 246238087.
Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. (March 2021). "Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials". Expert Opinion on Emerging Drugs. 26 (1): 63–74. doi:10.1080/14728214.2021.1898588. PMID 33682569. S2CID 232141396.
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. (February 2009). "Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis". Lancet. 373 (9665): 746–758. doi:10.1016/S0140-6736(09)60046-5. PMID 19185342. S2CID 35858125.
Monden R, Roest AM, van Ravenzwaaij D, Wagenmakers EJ, Morey R, Wardenaar KJ, et al. (August 2018). "The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews" (PDF). Journal of Affective Disorders. 235: 393–398. doi:10.1016/j.jad.2018.04.040. hdl:11370/842b1441-d0f3-4797-b95b-3a6a72262150. PMID 29677603. S2CID 5011570. Archived (PDF) from the original on 27 February 2022. Retrieved 13 December 2021.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. (April 2018). "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet. 391 (10128): 1357–1366. doi:10.1016/S0140-6736(17)32802-7. PMC 5889788. PMID 29477251.
Hengartner MP, Jakobsen JC, Sørensen A, Plöderl M (2020). "Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials". PLOS ONE. 15 (2): e0229381. Bibcode:2020PLoSO..1529381H. doi:10.1371/journal.pone.0229381. PMC 7043778. PMID 32101579.{{cite journal}}: CS1 maint: article number as page number (link)
Stone MB, Yaseen ZS, Miller BJ, Richardville K, Kalaria SN, Kirsch I (August 2022). "Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis". BMJ. 378: e067606. doi:10.1136/bmj-2021-067606. PMC 9344377. PMID 35918097.{{cite journal}}: CS1 maint: article number as page number (link)
Turner EH, Cipriani A, Furukawa TA, Salanti G, de Vries YA (January 2022). "Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials". PLOS Med. 19 (1): e1003886. doi:10.1371/journal.pmed.1003886. PMC 8769343. PMID 35045113.{{cite journal}}: CS1 maint: article number as page number (link)
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (January 2008). "Selective publication of antidepressant trials and its influence on apparent efficacy". N Engl J Med. 358 (3): 252–60. doi:10.1056/NEJMsa065779. PMID 18199864.
Gartlehner G, Nussbaumer-Streit B, Gaynes BN, Forneris CA, Morgan LC, Greenblatt A, et al. (March 2019). "Second-generation antidepressants for preventing seasonal affective disorder in adults". The Cochrane Database of Systematic Reviews. 3 (4): CD011268. doi:10.1002/14651858.CD011268.pub3. PMC 6422318. PMID 30883669.{{cite journal}}: CS1 maint: article number as page number (link)
Li DJ, Tseng PT, Chen YW, Wu CK, Lin PY (March 2016). "Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines". Medicine. 95 (13): e3165. doi:10.1097/MD.0000000000003165. PMC 4998539. PMID 27043678.{{cite journal}}: CS1 maint: article number as page number (link)
Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, et al. (August 2008). "Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies". The Journal of Clinical Psychiatry. 69 (8): 1287–1292. doi:10.4088/JCP.v69n0812. PMID 18605812. S2CID 25267685.
Naguy A, Badr BHM (October 2022). "Bupropion-myth-busting!". CNS Spectr. 27 (5): 545–546. doi:10.1017/S1092852921000365. PMID 33843549. S2CID 233212535.
Ruberto VL, Jha MK, Murrough JW (June 2020). "Pharmacological Treatments for Patients with Treatment-Resistant Depression". Pharmaceuticals. 13 (6): 116. doi:10.3390/ph13060116. PMC 7345023. PMID 32512768.
Wilkes S (2008). "The use of bupropion SR in cigarette smoking cessation". International Journal of Chronic Obstructive Pulmonary Disease. 3 (1): 45–53. doi:10.2147/copd.s1121. PMC 2528204. PMID 18488428.
Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, et al. (May 2023). "Antidepressants for smoking cessation". The Cochrane Database of Systematic Reviews. 2023 (5): CD000031. doi:10.1002/14651858.CD000031.pub6. PMC 10207863. PMID 37230961.{{cite journal}}: CS1 maint: article number as page number (link)
Wu P, Wilson K, Dimoulas P, Mills EJ (December 2006). "Effectiveness of smoking cessation therapies: a systematic review and meta-analysis". BMC Public Health. 6 300. doi:10.1186/1471-2458-6-300. PMC 1764891. PMID 17156479.
Mooney ME, Sofuoglu M (July 2006). "Bupropion for the treatment of nicotine withdrawal and craving". Expert Review of Neurotherapeutics. 6 (7): 965–981. doi:10.1586/14737175.6.7.965. PMID 16831112. S2CID 19195413.
Rosen LJ, Galili T, Kott J, Goodman M, Freedman LS (May 2018). "Diminishing benefit of smoking cessation medications during the first year: a meta-analysis of randomized controlled trials". Addiction. 113 (5): 805–816. doi:10.1111/add.14134. PMC 5947828. PMID 29377409.
Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Chubb E, et al. (October 2019). "Relapse prevention interventions for smoking cessation". The Cochrane Database of Systematic Reviews. 2019 (10). doi:10.1002/14651858.CD003999.pub6. PMC 6816175. PMID 31684681.
Patnode CD, Henderson JT, Coppola EL, Melnikow J, Durbin S, Thomas RG (January 2021). "Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 325 (3): 280–298. doi:10.1001/jama.2020.23541. PMID 33464342.
Selph S, Patnode C, Bailey SR, Pappas M, Stoner R, Chou R (April 2020). "Primary Care-Relevant Interventions for Tobacco and Nicotine Use Prevention and Cessation in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 323 (16): 1599–1608. doi:10.1001/jama.2020.3332. PMID 32343335.
Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J, et al. (March 2020). "Pharmacological interventions for promoting smoking cessation during pregnancy". The Cochrane Database of Systematic Reviews. 2020 (3): CD010078. doi:10.1002/14651858.CD010078.pub3. PMC 7059898. PMID 32129504.{{cite journal}}: CS1 maint: article number as page number (link)
Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. (October 2019). "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Pediatrics. 144 (4) e20192528. doi:10.1542/peds.2019-2528. PMC 7067282. PMID 31570648.
Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, et al. (2020). "Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis". PLOS ONE. 15 (10): e0240584. Bibcode:2020PLoSO..1540584E. doi:10.1371/journal.pone.0240584. PMC 7577505. PMID 33085721.{{cite journal}}: CS1 maint: article number as page number (link)
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. (September 2018). "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis". The Lancet. Psychiatry. 5 (9): 727–738. doi:10.1016/S2215-0366(18)30269-4. PMC 6109107. PMID 30097390.
Ng QX (March 2017). "A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Journal of Child and Adolescent Psychopharmacology. 27 (2): 112–116. doi:10.1089/cap.2016.0124. PMID 27813651.
Wilens TE, Morrison NR, Prince J (October 2011). "An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults". Expert Review of Neurotherapeutics. 11 (10): 1443–1465. doi:10.1586/ern.11.137. PMC 3229037. PMID 21955201.
Serretti A, Chiesa A (June 2009). "Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis". Journal of Clinical Psychopharmacology. 29 (3): 259–266. doi:10.1097/JCP.0b013e3181a5233f. PMID 19440080. S2CID 1663570.
Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S (2004). "A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor". Primary Care Companion to the Journal of Clinical Psychiatry. 6 (4): 159–166. doi:10.4088/PCC.v06n0403. PMC 514842. PMID 15361919.
Basson R, Gilks T (2018). "Women's sexual dysfunction associated with psychiatric disorders and their treatment". Women's Health. 14 1745506518762664. doi:10.1177/1745506518762664. PMC 5900810. PMID 29649948.
Clayton AH, Kingsberg SA, Goldstein I (June 2018). "Evaluation and Management of Hypoactive Sexual Desire Disorder". Sexual Medicine. 6 (2): 59–74. doi:10.1016/j.esxm.2018.01.004. PMC 5960024. PMID 29523488.
Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, et al. (January 2017). "Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review". Mayo Clinic Proceedings. 92 (1): 114–128. doi:10.1016/j.mayocp.2016.09.018. PMID 27916394.
Razali NA, Sidi H, Choy CL, Ross NA, Baharudin A, Das S (February 2022). "The Role of Bupropion in the Treatment of Women with Sexual Desire Disorder: A Systematic Review and Meta-Analysis". Curr Neuropharmacol. 20 (10): 1941–1955. doi:10.2174/1570159X20666220222145735. PMC 9886814. PMID 35193485. S2CID 247057961.
Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. (April 2005). "Meta-analysis: pharmacologic treatment of obesity". Annals of Internal Medicine. 142 (7): 532–546. doi:10.7326/0003-4819-142-7-200504050-00012. PMID 15809465.
Kampman KM (June 2008). "The search for medications to treat stimulant dependence". Addiction Science & Clinical Practice. 4 (2): 28–35. doi:10.1151/ascp084228 (inactive 11 July 2025). PMC 2797110. PMID 18497715.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
Cao DN, Shi JJ, Hao W, Wu N, Li J (June 2016). "Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction". European Journal of Pharmacology. 780: 129–135. doi:10.1016/j.ejphar.2016.03.040. PMID 27018393.
Akbar D, Rhee TG, Ceban F, Ho R, Teopiz KM, Cao B, et al. (October 2023). "Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials". CNS Drugs. 37 (10): 867–881. doi:10.1007/s40263-023-01032-5. PMID 37792265.
Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ (September 2006). "Antidepressants and inflammatory bowel disease: a systematic review". Clinical Practice and Epidemiology in Mental Health. 2: 24. doi:10.1186/1745-0179-2-24. PMC 1599716. PMID 16984660.
Thorkelson G, Bielefeldt K, Szigethy E (June 2016). "Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD". Inflammatory Bowel Diseases. 22 (6): 1509–1522. doi:10.1097/MIB.0000000000000734. PMID 27167571.
Eskeland S, Halvorsen JA, Tanum L (August 2017). "Antidepressants have Anti-inflammatory Effects that may be Relevant to Dermatology: A Systematic Review". Acta Dermato-Venereologica. 97 (8): 897–905. doi:10.2340/00015555-2702. hdl:10852/63759. PMID 28512664.
Ferraro MC, Urquhart DM, Ferreira GE, Wewege MA, Abdel Shaheed C, Traeger AC, et al. (2025). "Antidepressants for low back pain and spine-related leg pain". The Cochrane Database of Systematic Reviews. 2025 (3): CD001703. doi:10.1002/14651858.CD001703.pub4. PMC 11890917. PMID 40058767.{{cite journal}}: CS1 maint: article number as page number (link)
Ono T, Takenoshita S, Nishino S (September 2022). "Pharmacologic Management of Excessive Daytime Sleepiness". Sleep Med Clin. 17 (3): 485–503. doi:10.1016/j.jsmc.2022.06.012. PMID 36150809.
Rye DB, Dihenia B, Bliwise DL (1998). "Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion". Depress Anxiety. 7 (2): 92–95. doi:10.1002/(SICI)1520-6394(1998)7:2<92::AID-DA9>3.0.CO;2-7. PMID 9614600.
Goksan B, Mercan S, Karamustafalioglu O (2005). "Bupropion is effective in depression in narcolepsy". Int J Psychiatry Clin Pract. 9 (4): 289–291. doi:10.1080/13651500500241454. PMID 24930928.
Marin RS, Wilkosz PA (2005). "Disorders of diminished motivation". J Head Trauma Rehabil. 20 (4): 377–88. doi:10.1097/00001199-200507000-00009. PMID 16030444.
Lyonga Ngonge A, Nyange C, Ghali JK (February 2024). "Novel pharmacotherapeutic options for the treatment of postural orthostatic tachycardia syndrome". Expert Opin Pharmacother. 25 (2): 181–188. doi:10.1080/14656566.2024.2319224. PMID 38465412.
Vyas R, Nesheiwat Z, Ruzieh M, Ammari Z, Al-Sarie M, Grubb B (August 2020). "Bupropion in the treatment of postural orthostatic tachycardia syndrome (POTS): a single-center experience". J Investig Med. 68 (6): 1156–1158. doi:10.1136/jim-2020-001272. PMID 32606041.
Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. (March 2021). "Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials". Expert Opinion on Emerging Drugs. 26 (1): 63–74. doi:10.1080/14728214.2021.1898588. PMID 33682569. S2CID 232141396.
Alberti S, Chiesa A, Andrisano C, Serretti A (June 2015). "Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis". Journal of Clinical Psychopharmacology. 35 (3): 296–303. doi:10.1097/JCP.0000000000000329. PMID 25874915. S2CID 33102792. Archived from the original on 8 March 2023. Retrieved 13 November 2022.
Telang S, Walton C, Olten B, Bloch MH (August 2018). "Meta-analysis: Second generation antidepressants and headache". Journal of Affective Disorders. 236: 60–68. doi:10.1016/j.jad.2018.04.047. PMID 29715610. S2CID 19196303.
Kittle J, Lopes RD, Huang M, Marquess ML, Wilson MD, Ascher J, et al. (October 2017). "Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort". Clinical Cardiology. 40 (10): 899–906. doi:10.1002/clc.22744. PMC 6490529. PMID 28605035.
Grandi SM, Shimony A, Eisenberg MJ (December 2013). "Bupropion for smoking cessation in patients hospitalized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials". The Canadian Journal of Cardiology. 29 (12): 1704–1711. doi:10.1016/j.cjca.2013.09.014. PMID 24267809.
Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R (2002). "Effects of psychotropic drugs on seizure threshold". Drug Safety. 25 (2): 91–110. doi:10.2165/00002018-200225020-00004. PMID 11888352. S2CID 25290793.
Wu A, Khawaja AP, Pasquale LR, Stein JD (January 2020). "A review of systemic medications that may modulate the risk of glaucoma". Eye. 34 (1): 12–28. doi:10.1038/s41433-019-0603-z. PMC 7002596. PMID 31595027.
"Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss". Prescrire International. 24 (164): 229–233. October 2015. PMID 26594724.
Herstowska M, Komorowska O, Cubała WJ, Jakuszkowiak-Wojten K, Gałuszko-Węgielnik M, Landowski J (May 2014). "Severe skin complications in patients treated with antidepressants: a literature review". Postepy Dermatologii I Alergologii. 31 (2): 92–97. doi:10.5114/pdia.2014.40930. PMC 4112250. PMID 25097474.
Goodnick PJ, Jerry J, Parra F (May 2002). "Psychotropic drugs and the ECG: focus on the QTc interval". Expert Opin Pharmacother. 3 (5): 479–498. doi:10.1517/14656566.3.5.479. PMID 11996627.
Jasiak NM, Bostwick JR (December 2014). "Risk of QT/QTc prolongation among newer non-SSRI antidepressants". Ann Pharmacother. 48 (12): 1620–1628. doi:10.1177/1060028014550645. PMID 25204465.
Caillier B, Pilote S, Castonguay A, Patoine D, Ménard-Desrosiers V, Vigneault P, et al. (October 2012). "QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile". Fundam Clin Pharmacol. 26 (5): 599–608. doi:10.1111/j.1472-8206.2011.00953.x. PMID 21623902.
Henssler J, Heinz A, Brandt L, Bschor T (May 2019). "Antidepressant Withdrawal and Rebound Phenomena". Deutsches Ärzteblatt International. 116 (20): 355–361. doi:10.3238/arztebl.2019.0355. PMC 6637660. PMID 31288917.
White N, Litovitz T, Clancy C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type". Journal of Medical Toxicology. 4 (4): 238–250. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
Jefferson JW, Pradko JF, Muir KT (November 2005). "Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations". Clinical Therapeutics. 27 (11): 1685–1695. doi:10.1016/j.clinthera.2005.11.011. PMID 16368442.
Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS, et al. (October 1995). "Carbamazepine but not valproate induces bupropion metabolism". Journal of Clinical Psychopharmacology. 15 (5): 327–333. doi:10.1097/00004714-199510000-00004. PMID 8830063.
Todor I, Popa A, Neag M, Muntean D, Bocsan C, Buzoianu A, et al. (2016). "Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers". Journal of Pharmacy & Pharmaceutical Sciences. 19 (2): 198–207. doi:10.18433/J3H03R. PMID 27518170.
Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, et al. (April 2015). "Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects". The Journal of Pharmacology and Experimental Therapeutics. 353 (1): 102–111. doi:10.1124/jpet.114.222356. PMID 25655950. S2CID 14761997.
Protti M, Mandrioli R, Marasca C, Cavalli A, Serretti A, Mercolini L (September 2020). "New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others". Medicinal Research Reviews. 40 (5): 1794–1832. doi:10.1002/med.21671. hdl:11585/762375. PMID 32285503. S2CID 215758102.
Spina E, Santoro V, D'Arrigo C (July 2008). "Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update". Clinical Therapeutics. 30 (7): 1206–1227. doi:10.1016/s0149-2918(08)80047-1. PMID 18691982.
Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008). "Pharmacotherapy of methamphetamine addiction: an update". Subst Abus. 29 (3): 31–49. Bibcode:2008JPkR...29...31E. doi:10.1080/08897070802218554. PMC 2597382. PMID 19042205.
Simmler LD, Wandeler R, Liechti ME (June 2013). "Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence". BMC Res Notes. 6 220. doi:10.1186/1756-0500-6-220. PMC 3679734. PMID 23734766.
Newton TF, Roache JD, De La Garza R, Fong T, Wallace CL, Li SH, et al. (July 2006). "Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving". Neuropsychopharmacology. 31 (7): 1537–1544. doi:10.1038/sj.npp.1300979. PMID 16319910.
Feinberg SS (November 2004). "Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication". The Journal of Clinical Psychiatry. 65 (11): 1520–1524. doi:10.4088/jcp.v65n1113. PMID 15554766.
Richelson E, Nelson A (July 1984). "Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro". J Pharmacol Exp Ther. 230 (1): 94–102. doi:10.1016/S0022-3565(25)21446-X. PMID 6086881.
Wander TJ, Nelson A, Okazaki H, Richelson E (December 1986). "Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro". Eur J Pharmacol. 132 (2–3): 115–121. doi:10.1016/0014-2999(86)90596-0. PMID 3816971.
Cusack B, Nelson A, Richelson E (May 1994). "Binding of antidepressants to human brain receptors: focus on newer generation compounds". Psychopharmacology (Berl). 114 (4): 559–565. doi:10.1007/BF02244985. PMID 7855217.
Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur J Pharmacol. 340 (2–3): 249–258. doi:10.1016/s0014-2999(97)01393-9. PMID 9537821.
Sánchez C, Hyttel J (August 1999). "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". Cell Mol Neurobiol. 19 (4): 467–489. doi:10.1023/a:1006986824213. PMC 11545528. PMID 10379421.
Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, et al. (September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors". Mol Pharmacol. 66 (3): 675–682. doi:10.1124/mol.104.001313. PMID 15322260.
Shalabi AR, Walther D, Baumann MH, Glennon RA (June 2017). "Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release". ACS Chemical Neuroscience. 8 (6): 1397–1403. doi:10.1021/acschemneuro.7b00055. PMC 7261150. PMID 28220701.
Hart XM, Spangemacher M, Defert J, Uchida H, Gründer G (April 2024). "Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants". Ther Drug Monit. 46 (2): 155–169. doi:10.1097/FTD.0000000000001142. PMID 38287888.
Egerton A, Shotbolt JP, Stokes PR, Hirani E, Ahmad R, Lappin JM, et al. (March 2010). "Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study". NeuroImage. 50 (1): 260–266. doi:10.1016/j.neuroimage.2009.11.077. PMC 4135078. PMID 19969097.
Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, et al. (November 2005). "Bupropion increases striatal vesicular monoamine transport". Neuropharmacology. New Perspectives in Neurotransmitter Transporter Biology. 49 (6): 820–830. doi:10.1016/j.neuropharm.2005.05.004. PMID 16005476. S2CID 26035635.
Lukas RJ, Muresan AZ, Damaj MI, Blough BE, Huang X, Navarro HA, et al. (June 2010). "Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation". Journal of Medicinal Chemistry. 53 (12): 4731–4748. doi:10.1021/jm1003232. PMC 2895766. PMID 20509659.
Andersen J, Ringsted KB, Bang-Andersen B, Strømgaard K, Kristensen AS (27 October 2015). "Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter". Scientific Reports. 5 (1) 15650. Bibcode:2015NatSR...515650A. doi:10.1038/srep15650. ISSN 2045-2322. PMC 4621520. PMID 26503701.
Sałaciak K, Pytka K (January 2022). "Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders". Neurosci Biobehav Rev. 132: 1114–1136. doi:10.1016/j.neubiorev.2021.10.037. PMC 8559442. PMID 34736882.
Dhir A, Kulkarni SK (August 2008). "Possible involvement of sigma-1 receptors in the anti-immobility action of bupropion, a dopamine reuptake inhibitor". Fundam Clin Pharmacol. 22 (4): 387–394. doi:10.1111/j.1472-8206.2008.00605.x. PMID 18705749.
Brimson JM, Brimson S, Chomchoei C, Tencomnao T (October 2020). "Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain". Expert Opin Ther Targets. 24 (10): 1009–1028. doi:10.1080/14728222.2020.1805435. PMID 32746649. AXS-05 is a combination of dextromethorphan and bupropion and has been shown to have a rapid (within one week) positive effect in patients with depression. Dextromethorphan, as described above as part of Nuedexta, is a σ-1R agonist, an NMDA antagonist, and has an affinity for the serotonin reuptake transporter. Whereas, bupropion is a moderately effective antidepressant when taken alone, thought to act by preventing dopamine and noradrenaline reuptake [230]. Studies in mice have shown that the antidepressant-like effects of bupropion are potentiated by σ-1R agonists, and inhibited by σ-1R antagonists [231]. These findings suggest that the combination of a σ-1R agonist and the dopamine/ noradrenaline reuptake inhibitor will be more effective than either treatment alone.
Pei Y, Asif-Malik A, Canales JJ (2016). "Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications". Front Neurosci. 10: 148. doi:10.3389/fnins.2016.00148. PMC 4820462. PMID 27092049.
Docherty JR, Alsufyani HA (August 2021). "Pharmacology of Drugs Used as Stimulants". J Clin Pharmacol. 61 (Suppl 2): S53 – S69. doi:10.1002/jcph.1918. PMID 34396557. Many stimulants have potency at the rat TAAR1 in the micromolar range but tend to be about 5 to 10 times less potent at the human TAAR1, but bupropion was found to be inactive.87,88
Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1" (PDF). J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID 26791601. Archived from the original (PDF) on 9 May 2025.
Wainscott DB, Little SP, Yin T, Tu Y, Rocco VP, He JX, et al. (January 2007). "Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1". J Pharmacol Exp Ther. 320 (1): 475–485. doi:10.1124/jpet.106.112532. PMID 17038507.
Strawbridge R, Izurieta E, Day E, Tee H, Young K, Tong CC, et al. (2023). "Peripheral inflammatory effects of different interventions for treatment-resistant depression: A systematic review". Neuroscience Applied. 2 101014. Elsevier BV. doi:10.1016/j.nsa.2022.101014. ISSN 2772-4085. PMC 12244173. PMID 40655965. S2CID 253283525.
Hajhashemi V, Khanjani P (2014). "Analgesic and anti-inflammatory activities of bupropion in animal models". Res Pharm Sci. 9 (4): 251–7. PMC 4314873. PMID 25657796.
Karimollah A, Hemmatpur A, Vahid T (August 2021). "Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3". Inflammopharmacology. 29 (4): 1101–1109. doi:10.1007/s10787-021-00829-4. PMID 34218389. S2CID 234883621.
Yetkin D, Yılmaz İA, Ayaz F (September 2023). "Anti-inflammatory activity of bupropion through immunomodulation of the macrophages". Naunyn-Schmiedeberg's Arch Pharmacol. 396 (9): 2087–2093. doi:10.1007/s00210-023-02462-0. PMID 36928557. S2CID 257583439.
Chen WC, Lai HC, Su WP, Palani M, Su KP (January 2015). "Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: an open-label study". Psychiatry Investig. 12 (1): 142–5. doi:10.4306/pi.2015.12.1.142. PMC 4310912. PMID 25670957.
Cámara-Lemarroy CR, Guzmán-de la Garza FJ, Cordero-Pérez P, Alarcón-Galván G, Ibarra-Hernández JM, Muñoz-Espinosa LE, et al. (2013). "Bupropion reduces the inflammatory response and intestinal injury due to ischemia-reperfusion". Transplant Proc. 45 (6): 2502–5. doi:10.1016/j.transproceed.2013.04.010. PMID 23953570.
Tafseer S, Gupta R, Ahmad R, Jain S, Bhatia MS, Gupta LK (January 2021). "Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder". Pharmacol Biochem Behav. 200 173073. doi:10.1016/j.pbb.2020.173073. PMID 33186562. S2CID 226292409.
Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB (June 2006). "A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice". Int Immunopharmacol. 6 (6): 903–7. doi:10.1016/j.intimp.2005.12.007. PMID 16644475. Archived from the original on 16 October 2023. Retrieved 25 October 2023.
Kharasch ED, Neiner A, Kraus K, Blood J, Stevens A, Schweiger J, et al. (May 2019). "Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial". Clinical Pharmacology and Therapeutics. 105 (5): 1164–1174. doi:10.1002/cpt.1309. PMC 6465131. PMID 30460996.
Kharasch ED, Neiner A, Kraus K, Blood J, Stevens A, Miller JP, et al. (November 2020). "Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults". Clinical Pharmacology and Therapeutics. 108 (5): 1036–1048. doi:10.1002/cpt.1888. PMID 32386065. S2CID 218563059.
Sánchez C, Hyttel J (August 1999). "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". Cellular and Molecular Neurobiology. 19 (4): 467–489. doi:10.1023/a:1006986824213. PMC 11545528. PMID 10379421. S2CID 19490821.
Bondarev ML, Bondareva TS, Young R, Glennon RA (August 2003). "Behavioral and biochemical investigations of bupropion metabolites". European Journal of Pharmacology. 474 (1): 85–93. doi:10.1016/S0014-2999(03)02010-7. PMID 12909199.
Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, et al. (September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors". Molecular Pharmacology. 66 (3): 675–682. doi:10.1124/mol.104.001313. PMID 15322260. S2CID 1577336.
Stuebler AG, Jansen M (March 2020). "Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations". Molecular Pharmacology. 97 (3): 171–179. doi:10.1124/mol.119.118349. PMC 6978693. PMID 31871303.
Pandhare A, Pappu AS, Wilms H, Blanton MP, Jansen M (February 2017). "The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors". Neuropharmacology. 113 (Pt A): 89–99. doi:10.1016/j.neuropharm.2016.09.021. PMC 5148637. PMID 27671323.
Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, et al. (April 2004). "Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes". Pharmacogenetics. 14 (4): 225–238. doi:10.1097/00008571-200404000-00002. PMID 15083067.
Preskorn SH (1991). "Should bupropion dosage be adjusted based upon therapeutic drug monitoring?". Psychopharmacology Bulletin. 27 (4): 637–643. PMID 1813908.
Bryant SG, Guernsey BG, Ingrim NB (1983). "Review of bupropion". Clinical Pharmacy. 2 (6): 525–37. PMID 6140095.
Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI (2014). "Bupropion and bupropion analogs as treatments for CNS disorders". Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Adv Pharmacol. Vol. 69. pp. 177–216. doi:10.1016/B978-0-12-420118-7.00005-6. ISBN 978-0-12-420118-7. PMID 24484978.
Costa R, Oliveira NG, Dinis-Oliveira RJ (August 2019). "Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects". Drug Metab Rev. 51 (3): 293–313. doi:10.1080/03602532.2019.1620763. PMID 31124380.
Welch RM, Lai AA, Schroeder DH (March 1987). "Pharmacological significance of the species differences in bupropion metabolism". Xenobiotica. 17 (3): 287–298. doi:10.3109/00498258709043939. PMID 3107223.
Naglich AC, Brown ES, Adinoff B (2019). "Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential". Am J Drug Alcohol Abuse. 45 (4): 341–354. doi:10.1080/00952990.2018.1545023. PMID 30601027.
Musso DL, Mehta NB, Soroko FE, Ferris RM, Hollingsworth EB, Kenney BT (1993). "Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion". Chirality. 5 (7): 495–500. doi:10.1002/chir.530050704. PMID 8240925.
Glennon RA (2014). "Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention". Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Adv Pharmacol. Vol. 69. pp. 581–620. doi:10.1016/B978-0-12-420118-7.00015-9. ISBN 978-0-12-420118-7. PMC 4471862. PMID 24484988. Bupropion, the N-tert-butyl analog of 3-chlorocathinone, is a clinically employed antidepressant.
Shalabi AR, Walther D, Baumann MH, Glennon RA (June 2017). "Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release". ACS Chem Neurosci. 8 (6): 1397–1403. doi:10.1021/acschemneuro.7b00055. PMC 7261150. PMID 28220701.
Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA (April 2021). "Designer drugs: a medicinal chemistry perspective (II)". Ann N Y Acad Sci. 1489 (1): 48–77. Bibcode:2021NYASA1489...48C. doi:10.1111/nyas.14349. PMID 32396701.
Carroll FI, Blough BE, Abraham P, Mills AC, Holleman JA, Wolckenhauer SA, et al. (November 2009). "Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction". J Med Chem. 52 (21): 6768–6781. doi:10.1021/jm901189z. PMID 19821577.
Blough BE, Landavazo A, Partilla JS, Baumann MH, Decker AM, Page KM, et al. (June 2014). "Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics". ACS Med Chem Lett. 5 (6): 623–627. doi:10.1021/ml500113s. PMC 4060932. PMID 24944732.
Weintraub D, Linder MW (2000). "Amphetamine positive toxicology screen secondary to bupropion". Depression and Anxiety. 12 (1): 53–54. doi:10.1002/1520-6394(2000)12:1<53::AID-DA8>3.0.CO;2-4. PMID 10999247. S2CID 43480769.
Nixon AL, Long WH, Puopolo PR, Flood JG (June 1995). "Bupropion metabolites produce false-positive urine amphetamine results". Clinical Chemistry. 41 (6 Pt 1): 955–956. doi:10.1093/clinchem/41.6.955. PMID 7768026.
Casey ER, Scott MG, Tang S, Mullins ME (June 2011). "Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay". Journal of Medical Toxicology. 7 (2): 105–108. doi:10.1007/s13181-010-0131-5. PMC 3724447. PMID 21191682.
Naglich AC, Brown ES, Adinoff B (2019). "Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential". The American Journal of Drug and Alcohol Abuse. 45 (4): 341–354. doi:10.1080/00952990.2018.1545023. PMID 30601027. S2CID 58587857.
Phillips D (February 2012). "Wellbutrin®: misuse and abuse by incarcerated individuals". Journal of Addictions Nursing. 23 (1): 65–69. doi:10.3109/10884602.2011.647838. PMID 22468662. S2CID 1310940.
Baribeau D, Araki KF (May–June 2013). "Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent". Journal of Addiction Medicine. 7 (3): 216–217. doi:10.1097/ADM.0b013e3182824863. PMID 23519045.
Stassinos GL, Klein-Schwartz W (2016). "Bupropion "Abuse" Reported to US Poison Centers". Journal of Addiction Medicine. 10 (5): 357–362. doi:10.1097/ADM.0000000000000249. PMID 27504927. S2CID 24870292.
Schneier FR (March 2011). "Pharmacotherapy of social anxiety disorder". Expert Opin Pharmacother. 12 (4): 615–625. doi:10.1517/14656566.2011.534983. PMID 21241211.
Emmanuel NP, Lydiard RB, Ballenger JC (August 1991). "Treatment of social phobia with bupropion". J Clin Psychopharmacol. 11 (4): 276–277. doi:10.1097/00004714-199108000-00023. PMID 1918431.
Emmanuel NP, Brawman-Mintzer O, Morton WA, Book SW, Johnson MR, Lorberbaum JP, et al. (2000). "Bupropion-SR in treatment of social phobia". Depress Anxiety. 12 (2): 111–113. doi:10.1002/1520-6394(2000)12:2<111::AID-DA9>3.0.CO;2-3. PMID 11091936.

ncbi.nlm.nih.gov

Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. (2005). "15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL". Primary Care Companion to the Journal of Clinical Psychiatry. 7 (3): 106–113. doi:10.4088/pcc.v07n0305. PMC 1163271. PMID 16027765.
Masters AR, Gufford BT, Lu JB, Metzger IF, Jones DR, Desta Z (August 2016). "Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers". The Journal of Pharmacology and Experimental Therapeutics. 358 (2): 230–238. doi:10.1124/jpet.116.232876. PMC 4959100. PMID 27255113.
Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK (April 2016). "Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant". Therapeutic Advances in Psychopharmacology. 6 (2): 99–144. doi:10.1177/2045125316629071. PMC 4837968. PMID 27141292.
Arandjelovic K, Eyre HA, Lavretsky H (October 2016). "Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports". The American Journal of Geriatric Psychiatry. 24 (10): 913–917. doi:10.1016/j.jagp.2016.05.010. PMC 5540329. PMID 27591914.
Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C (October 2017). "Bupropion for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2017 (10): CD009504. doi:10.1002/14651858.CD009504.pub2. PMC 6485546. PMID 28965364.{{cite journal}}: CS1 maint: article number as page number (link)
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. (April 2018). "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet. 391 (10128): 1357–1366. doi:10.1016/S0140-6736(17)32802-7. PMC 5889788. PMID 29477251.
Hengartner MP, Jakobsen JC, Sørensen A, Plöderl M (2020). "Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials". PLOS ONE. 15 (2): e0229381. Bibcode:2020PLoSO..1529381H. doi:10.1371/journal.pone.0229381. PMC 7043778. PMID 32101579.{{cite journal}}: CS1 maint: article number as page number (link)
Stone MB, Yaseen ZS, Miller BJ, Richardville K, Kalaria SN, Kirsch I (August 2022). "Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis". BMJ. 378: e067606. doi:10.1136/bmj-2021-067606. PMC 9344377. PMID 35918097.{{cite journal}}: CS1 maint: article number as page number (link)
Turner EH, Cipriani A, Furukawa TA, Salanti G, de Vries YA (January 2022). "Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials". PLOS Med. 19 (1): e1003886. doi:10.1371/journal.pmed.1003886. PMC 8769343. PMID 35045113.{{cite journal}}: CS1 maint: article number as page number (link)
Gartlehner G, Nussbaumer-Streit B, Gaynes BN, Forneris CA, Morgan LC, Greenblatt A, et al. (March 2019). "Second-generation antidepressants for preventing seasonal affective disorder in adults". The Cochrane Database of Systematic Reviews. 3 (4): CD011268. doi:10.1002/14651858.CD011268.pub3. PMC 6422318. PMID 30883669.{{cite journal}}: CS1 maint: article number as page number (link)
Li DJ, Tseng PT, Chen YW, Wu CK, Lin PY (March 2016). "Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines". Medicine. 95 (13): e3165. doi:10.1097/MD.0000000000003165. PMC 4998539. PMID 27043678.{{cite journal}}: CS1 maint: article number as page number (link)
Ruberto VL, Jha MK, Murrough JW (June 2020). "Pharmacological Treatments for Patients with Treatment-Resistant Depression". Pharmaceuticals. 13 (6): 116. doi:10.3390/ph13060116. PMC 7345023. PMID 32512768.
Wilkes S (2008). "The use of bupropion SR in cigarette smoking cessation". International Journal of Chronic Obstructive Pulmonary Disease. 3 (1): 45–53. doi:10.2147/copd.s1121. PMC 2528204. PMID 18488428.
Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, et al. (May 2023). "Antidepressants for smoking cessation". The Cochrane Database of Systematic Reviews. 2023 (5): CD000031. doi:10.1002/14651858.CD000031.pub6. PMC 10207863. PMID 37230961.{{cite journal}}: CS1 maint: article number as page number (link)
Wu P, Wilson K, Dimoulas P, Mills EJ (December 2006). "Effectiveness of smoking cessation therapies: a systematic review and meta-analysis". BMC Public Health. 6 300. doi:10.1186/1471-2458-6-300. PMC 1764891. PMID 17156479.
Rosen LJ, Galili T, Kott J, Goodman M, Freedman LS (May 2018). "Diminishing benefit of smoking cessation medications during the first year: a meta-analysis of randomized controlled trials". Addiction. 113 (5): 805–816. doi:10.1111/add.14134. PMC 5947828. PMID 29377409.
Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Chubb E, et al. (October 2019). "Relapse prevention interventions for smoking cessation". The Cochrane Database of Systematic Reviews. 2019 (10). doi:10.1002/14651858.CD003999.pub6. PMC 6816175. PMID 31684681.
Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J, et al. (March 2020). "Pharmacological interventions for promoting smoking cessation during pregnancy". The Cochrane Database of Systematic Reviews. 2020 (3): CD010078. doi:10.1002/14651858.CD010078.pub3. PMC 7059898. PMID 32129504.{{cite journal}}: CS1 maint: article number as page number (link)
Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. (October 2019). "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Pediatrics. 144 (4) e20192528. doi:10.1542/peds.2019-2528. PMC 7067282. PMID 31570648.
Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, et al. (2020). "Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis". PLOS ONE. 15 (10): e0240584. Bibcode:2020PLoSO..1540584E. doi:10.1371/journal.pone.0240584. PMC 7577505. PMID 33085721.{{cite journal}}: CS1 maint: article number as page number (link)
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. (September 2018). "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis". The Lancet. Psychiatry. 5 (9): 727–738. doi:10.1016/S2215-0366(18)30269-4. PMC 6109107. PMID 30097390.
Wilens TE, Morrison NR, Prince J (October 2011). "An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults". Expert Review of Neurotherapeutics. 11 (10): 1443–1465. doi:10.1586/ern.11.137. PMC 3229037. PMID 21955201.
Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S (2004). "A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor". Primary Care Companion to the Journal of Clinical Psychiatry. 6 (4): 159–166. doi:10.4088/PCC.v06n0403. PMC 514842. PMID 15361919.
Basson R, Gilks T (2018). "Women's sexual dysfunction associated with psychiatric disorders and their treatment". Women's Health. 14 1745506518762664. doi:10.1177/1745506518762664. PMC 5900810. PMID 29649948.
Clayton AH, Kingsberg SA, Goldstein I (June 2018). "Evaluation and Management of Hypoactive Sexual Desire Disorder". Sexual Medicine. 6 (2): 59–74. doi:10.1016/j.esxm.2018.01.004. PMC 5960024. PMID 29523488.
Razali NA, Sidi H, Choy CL, Ross NA, Baharudin A, Das S (February 2022). "The Role of Bupropion in the Treatment of Women with Sexual Desire Disorder: A Systematic Review and Meta-Analysis". Curr Neuropharmacol. 20 (10): 1941–1955. doi:10.2174/1570159X20666220222145735. PMC 9886814. PMID 35193485. S2CID 247057961.
Kampman KM (June 2008). "The search for medications to treat stimulant dependence". Addiction Science & Clinical Practice. 4 (2): 28–35. doi:10.1151/ascp084228 (inactive 11 July 2025). PMC 2797110. PMID 18497715.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ (September 2006). "Antidepressants and inflammatory bowel disease: a systematic review". Clinical Practice and Epidemiology in Mental Health. 2: 24. doi:10.1186/1745-0179-2-24. PMC 1599716. PMID 16984660.
Kittle J, Lopes RD, Huang M, Marquess ML, Wilson MD, Ascher J, et al. (October 2017). "Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort". Clinical Cardiology. 40 (10): 899–906. doi:10.1002/clc.22744. PMC 6490529. PMID 28605035.
Wu A, Khawaja AP, Pasquale LR, Stein JD (January 2020). "A review of systemic medications that may modulate the risk of glaucoma". Eye. 34 (1): 12–28. doi:10.1038/s41433-019-0603-z. PMC 7002596. PMID 31595027.
Herstowska M, Komorowska O, Cubała WJ, Jakuszkowiak-Wojten K, Gałuszko-Węgielnik M, Landowski J (May 2014). "Severe skin complications in patients treated with antidepressants: a literature review". Postepy Dermatologii I Alergologii. 31 (2): 92–97. doi:10.5114/pdia.2014.40930. PMC 4112250. PMID 25097474.
Henssler J, Heinz A, Brandt L, Bschor T (May 2019). "Antidepressant Withdrawal and Rebound Phenomena". Deutsches Ärzteblatt International. 116 (20): 355–361. doi:10.3238/arztebl.2019.0355. PMC 6637660. PMID 31288917.
White N, Litovitz T, Clancy C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type". Journal of Medical Toxicology. 4 (4): 238–250. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008). "Pharmacotherapy of methamphetamine addiction: an update". Subst Abus. 29 (3): 31–49. Bibcode:2008JPkR...29...31E. doi:10.1080/08897070802218554. PMC 2597382. PMID 19042205.
Simmler LD, Wandeler R, Liechti ME (June 2013). "Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence". BMC Res Notes. 6 220. doi:10.1186/1756-0500-6-220. PMC 3679734. PMID 23734766.
Sánchez C, Hyttel J (August 1999). "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". Cell Mol Neurobiol. 19 (4): 467–489. doi:10.1023/a:1006986824213. PMC 11545528. PMID 10379421.
Shalabi AR, Walther D, Baumann MH, Glennon RA (June 2017). "Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release". ACS Chemical Neuroscience. 8 (6): 1397–1403. doi:10.1021/acschemneuro.7b00055. PMC 7261150. PMID 28220701.
Egerton A, Shotbolt JP, Stokes PR, Hirani E, Ahmad R, Lappin JM, et al. (March 2010). "Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study". NeuroImage. 50 (1): 260–266. doi:10.1016/j.neuroimage.2009.11.077. PMC 4135078. PMID 19969097.
Lukas RJ, Muresan AZ, Damaj MI, Blough BE, Huang X, Navarro HA, et al. (June 2010). "Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation". Journal of Medicinal Chemistry. 53 (12): 4731–4748. doi:10.1021/jm1003232. PMC 2895766. PMID 20509659.
Andersen J, Ringsted KB, Bang-Andersen B, Strømgaard K, Kristensen AS (27 October 2015). "Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter". Scientific Reports. 5 (1) 15650. Bibcode:2015NatSR...515650A. doi:10.1038/srep15650. ISSN 2045-2322. PMC 4621520. PMID 26503701.
Sałaciak K, Pytka K (January 2022). "Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders". Neurosci Biobehav Rev. 132: 1114–1136. doi:10.1016/j.neubiorev.2021.10.037. PMC 8559442. PMID 34736882.
Pei Y, Asif-Malik A, Canales JJ (2016). "Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications". Front Neurosci. 10: 148. doi:10.3389/fnins.2016.00148. PMC 4820462. PMID 27092049.
Strawbridge R, Izurieta E, Day E, Tee H, Young K, Tong CC, et al. (2023). "Peripheral inflammatory effects of different interventions for treatment-resistant depression: A systematic review". Neuroscience Applied. 2 101014. Elsevier BV. doi:10.1016/j.nsa.2022.101014. ISSN 2772-4085. PMC 12244173. PMID 40655965. S2CID 253283525.
Hajhashemi V, Khanjani P (2014). "Analgesic and anti-inflammatory activities of bupropion in animal models". Res Pharm Sci. 9 (4): 251–7. PMC 4314873. PMID 25657796.
Chen WC, Lai HC, Su WP, Palani M, Su KP (January 2015). "Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: an open-label study". Psychiatry Investig. 12 (1): 142–5. doi:10.4306/pi.2015.12.1.142. PMC 4310912. PMID 25670957.
Kharasch ED, Neiner A, Kraus K, Blood J, Stevens A, Schweiger J, et al. (May 2019). "Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial". Clinical Pharmacology and Therapeutics. 105 (5): 1164–1174. doi:10.1002/cpt.1309. PMC 6465131. PMID 30460996.
Sánchez C, Hyttel J (August 1999). "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". Cellular and Molecular Neurobiology. 19 (4): 467–489. doi:10.1023/a:1006986824213. PMC 11545528. PMID 10379421. S2CID 19490821.
Stuebler AG, Jansen M (March 2020). "Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations". Molecular Pharmacology. 97 (3): 171–179. doi:10.1124/mol.119.118349. PMC 6978693. PMID 31871303.
Pandhare A, Pappu AS, Wilms H, Blanton MP, Jansen M (February 2017). "The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors". Neuropharmacology. 113 (Pt A): 89–99. doi:10.1016/j.neuropharm.2016.09.021. PMC 5148637. PMID 27671323.
Glennon RA (2014). "Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention". Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Adv Pharmacol. Vol. 69. pp. 581–620. doi:10.1016/B978-0-12-420118-7.00015-9. ISBN 978-0-12-420118-7. PMC 4471862. PMID 24484988. Bupropion, the N-tert-butyl analog of 3-chlorocathinone, is a clinically employed antidepressant.
Shalabi AR, Walther D, Baumann MH, Glennon RA (June 2017). "Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release". ACS Chem Neurosci. 8 (6): 1397–1403. doi:10.1021/acschemneuro.7b00055. PMC 7261150. PMID 28220701.
Blough BE, Landavazo A, Partilla JS, Baumann MH, Decker AM, Page KM, et al. (June 2014). "Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics". ACS Med Chem Lett. 5 (6): 623–627. doi:10.1021/ml500113s. PMC 4060932. PMID 24944732.
Casey ER, Scott MG, Tang S, Mullins ME (June 2011). "Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay". Journal of Medical Toxicology. 7 (2): 105–108. doi:10.1007/s13181-010-0131-5. PMC 3724447. PMID 21191682.

dailymed.nlm.nih.gov

"Wellbutrin SR – bupropion hydrochloride tablet, film coated". DailyMed. 5 November 2019. Archived from the original on 4 June 2020. Retrieved 6 May 2020.
"Wellbutrin XL- bupropion hydrochloride tablet, extended release". DailyMed. 4 March 2022. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
"Aplenzin – bupropion hydrobromide tablet, extended-release". DailyMed. 2 June 2020. Archived from the original on 26 October 2020. Retrieved 21 October 2020.
"Contrave Extended-Release – naltrexone hydrochloride and bupropion hydrochloride tablet, extended-release". DailyMed. 26 April 2019. Archived from the original on 4 June 2020. Retrieved 5 May 2020.
"Auvelity- dextromethorphan hydrobromide, bupropion hydrochloride tablet, multilayer, extended-release". DailyMed. 18 September 2024. Retrieved 17 October 2024.

pubchem.ncbi.nlm.nih.gov

"Bupropion". PubChem. United States National Library of Medicine – National Center for Biotechnology Information. 28 July 2018. Archived from the original on 29 July 2018. Retrieved 29 July 2018.
"Bupropion – Biological Test Results". PubChem. U.S. National Library of Medicine. Retrieved 19 August 2024.
"Bupropion". PubChem. Retrieved 4 August 2024.

nytimes.com (Global: 7^th place; English: 7^th place)

Thomas K, Schmidt MS (2 July 2012). "Glaxo agrees to pay $3 billion in fraud settlement". The New York Times. Archived from the original on 2 March 2017. Retrieved 26 February 2017.

peoplespharmacy.com (Global: low place; English: low place)

"Generic drug equality questioned". 12 October 2007. Archived from the original on 20 October 2012. Retrieved 13 October 2007.

pharmaceutical-journal.com (Global: low place; English: low place)

Lipanovic D (6 September 2023). "Bupropion to be made available in the UK again from December 2023, says manufacturer". The Pharmaceutical Journal. Archived from the original on 11 October 2023. Retrieved 24 October 2023.

primarypsychiatry.com (Global: low place; English: low place)

Clayton AH (2003). "Antidepressant-Associated Sexual Dysfunction: A Potentially Avoidable Therapeutic Challenge". Primary Psychiatry. 10 (1): 55–61. Archived from the original on 4 June 2020. Retrieved 21 March 2013.

psu.edu (Global: 207^th place; English: 136^th place)

citeseerx.ist.psu.edu

Lile JA, Nader MA (2003). "The abuse liability and therapeutic potential of drugs evaluated for cocaine addiction as predicted by animal models". Current Neuropharmacology. 1: 21–46. CiteSeerX 10.1.1.325.9635. doi:10.2174/1570159033360566.

sante.fr (Global: 8,603^rd place; English: low place)

agence-prd.ansm.sante.fr

"Autorisation – ZYBAN L.P. 150 mg, comprimé à libération prolongée". agence-prd.ansm.sante.fr (in French). Archived from the original on 9 April 2023. Retrieved 9 April 2023.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Costa R, Oliveira NG, Dinis-Oliveira RJ (August 2019). "Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects". Drug Metabolism Reviews. 51 (3): 293–313. doi:10.1080/03602532.2019.1620763. PMID 31124380. S2CID 163167323.
Dhillon S, Yang LP, Curran MP (2008). "Bupropion: a review of its use in the management of major depressive disorder". Drugs. 68 (5): 653–689. doi:10.2165/00003495-200868050-00011. PMID 18370448. S2CID 195687060.
Steinert T, Fröscher W (July 2018). "Epileptic Seizures Under Antidepressive Drug Treatment: Systematic Review". Pharmacopsychiatry. 51 (4): 121–135. doi:10.1055/s-0043-117962. PMID 28850959. S2CID 22436728.
De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E (March 2021). "A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants". Drug Safety. 44 (3): 291–312. doi:10.1007/s40264-020-01027-x. PMID 33354752. S2CID 229357583. Archived from the original on 7 March 2023. Retrieved 17 May 2022.
Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, et al. (October 2021). "Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants" (PDF). The World Journal of Biological Psychiatry. 22 (8): 561–628. doi:10.1080/15622975.2021.1878427. PMID 33977870. S2CID 234472488. Archived (PDF) from the original on 5 May 2022. Retrieved 10 April 2022.
Gautam M, Patel S, Zarkowski P (January 2022). "Practice patterns of bupropion co-prescription with antipsychotic medications". J Addict Dis. 40 (4): 481–488. doi:10.1080/10550887.2022.2028531. PMID 35068363. S2CID 246238087.
Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. (March 2021). "Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials". Expert Opinion on Emerging Drugs. 26 (1): 63–74. doi:10.1080/14728214.2021.1898588. PMID 33682569. S2CID 232141396.
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. (February 2009). "Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis". Lancet. 373 (9665): 746–758. doi:10.1016/S0140-6736(09)60046-5. PMID 19185342. S2CID 35858125.
Monden R, Roest AM, van Ravenzwaaij D, Wagenmakers EJ, Morey R, Wardenaar KJ, et al. (August 2018). "The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews" (PDF). Journal of Affective Disorders. 235: 393–398. doi:10.1016/j.jad.2018.04.040. hdl:11370/842b1441-d0f3-4797-b95b-3a6a72262150. PMID 29677603. S2CID 5011570. Archived (PDF) from the original on 27 February 2022. Retrieved 13 December 2021.
Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, et al. (August 2008). "Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies". The Journal of Clinical Psychiatry. 69 (8): 1287–1292. doi:10.4088/JCP.v69n0812. PMID 18605812. S2CID 25267685.
Naguy A, Badr BHM (October 2022). "Bupropion-myth-busting!". CNS Spectr. 27 (5): 545–546. doi:10.1017/S1092852921000365. PMID 33843549. S2CID 233212535.
Mooney ME, Sofuoglu M (July 2006). "Bupropion for the treatment of nicotine withdrawal and craving". Expert Review of Neurotherapeutics. 6 (7): 965–981. doi:10.1586/14737175.6.7.965. PMID 16831112. S2CID 19195413.
Serretti A, Chiesa A (June 2009). "Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis". Journal of Clinical Psychopharmacology. 29 (3): 259–266. doi:10.1097/JCP.0b013e3181a5233f. PMID 19440080. S2CID 1663570.
Razali NA, Sidi H, Choy CL, Ross NA, Baharudin A, Das S (February 2022). "The Role of Bupropion in the Treatment of Women with Sexual Desire Disorder: A Systematic Review and Meta-Analysis". Curr Neuropharmacol. 20 (10): 1941–1955. doi:10.2174/1570159X20666220222145735. PMC 9886814. PMID 35193485. S2CID 247057961.
Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. (March 2021). "Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials". Expert Opinion on Emerging Drugs. 26 (1): 63–74. doi:10.1080/14728214.2021.1898588. PMID 33682569. S2CID 232141396.
Alberti S, Chiesa A, Andrisano C, Serretti A (June 2015). "Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis". Journal of Clinical Psychopharmacology. 35 (3): 296–303. doi:10.1097/JCP.0000000000000329. PMID 25874915. S2CID 33102792. Archived from the original on 8 March 2023. Retrieved 13 November 2022.
Telang S, Walton C, Olten B, Bloch MH (August 2018). "Meta-analysis: Second generation antidepressants and headache". Journal of Affective Disorders. 236: 60–68. doi:10.1016/j.jad.2018.04.047. PMID 29715610. S2CID 19196303.
Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R (2002). "Effects of psychotropic drugs on seizure threshold". Drug Safety. 25 (2): 91–110. doi:10.2165/00002018-200225020-00004. PMID 11888352. S2CID 25290793.
Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, et al. (April 2015). "Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects". The Journal of Pharmacology and Experimental Therapeutics. 353 (1): 102–111. doi:10.1124/jpet.114.222356. PMID 25655950. S2CID 14761997.
Protti M, Mandrioli R, Marasca C, Cavalli A, Serretti A, Mercolini L (September 2020). "New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others". Medicinal Research Reviews. 40 (5): 1794–1832. doi:10.1002/med.21671. hdl:11585/762375. PMID 32285503. S2CID 215758102.
Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, et al. (November 2005). "Bupropion increases striatal vesicular monoamine transport". Neuropharmacology. New Perspectives in Neurotransmitter Transporter Biology. 49 (6): 820–830. doi:10.1016/j.neuropharm.2005.05.004. PMID 16005476. S2CID 26035635.
Strawbridge R, Izurieta E, Day E, Tee H, Young K, Tong CC, et al. (2023). "Peripheral inflammatory effects of different interventions for treatment-resistant depression: A systematic review". Neuroscience Applied. 2 101014. Elsevier BV. doi:10.1016/j.nsa.2022.101014. ISSN 2772-4085. PMC 12244173. PMID 40655965. S2CID 253283525.
Karimollah A, Hemmatpur A, Vahid T (August 2021). "Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3". Inflammopharmacology. 29 (4): 1101–1109. doi:10.1007/s10787-021-00829-4. PMID 34218389. S2CID 234883621.
Yetkin D, Yılmaz İA, Ayaz F (September 2023). "Anti-inflammatory activity of bupropion through immunomodulation of the macrophages". Naunyn-Schmiedeberg's Arch Pharmacol. 396 (9): 2087–2093. doi:10.1007/s00210-023-02462-0. PMID 36928557. S2CID 257583439.
Tafseer S, Gupta R, Ahmad R, Jain S, Bhatia MS, Gupta LK (January 2021). "Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder". Pharmacol Biochem Behav. 200 173073. doi:10.1016/j.pbb.2020.173073. PMID 33186562. S2CID 226292409.
Kharasch ED, Neiner A, Kraus K, Blood J, Stevens A, Miller JP, et al. (November 2020). "Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults". Clinical Pharmacology and Therapeutics. 108 (5): 1036–1048. doi:10.1002/cpt.1888. PMID 32386065. S2CID 218563059.
Sánchez C, Hyttel J (August 1999). "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". Cellular and Molecular Neurobiology. 19 (4): 467–489. doi:10.1023/a:1006986824213. PMC 11545528. PMID 10379421. S2CID 19490821.
Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, et al. (September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors". Molecular Pharmacology. 66 (3): 675–682. doi:10.1124/mol.104.001313. PMID 15322260. S2CID 1577336.
Weintraub D, Linder MW (2000). "Amphetamine positive toxicology screen secondary to bupropion". Depression and Anxiety. 12 (1): 53–54. doi:10.1002/1520-6394(2000)12:1<53::AID-DA8>3.0.CO;2-4. PMID 10999247. S2CID 43480769.
Naglich AC, Brown ES, Adinoff B (2019). "Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential". The American Journal of Drug and Alcohol Abuse. 45 (4): 341–354. doi:10.1080/00952990.2018.1545023. PMID 30601027. S2CID 58587857.
Phillips D (February 2012). "Wellbutrin®: misuse and abuse by incarcerated individuals". Journal of Addictions Nursing. 23 (1): 65–69. doi:10.3109/10884602.2011.647838. PMID 22468662. S2CID 1310940.
Stassinos GL, Klein-Schwartz W (2016). "Bupropion "Abuse" Reported to US Poison Centers". Journal of Addiction Medicine. 10 (5): 357–362. doi:10.1097/ADM.0000000000000249. PMID 27504927. S2CID 24870292.

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

ebs.tga.gov.au

"TGA eBS – Product and Consumer Medicine Information Licence". Archived from the original on 7 December 2016. Retrieved 9 January 2023.

unc.edu (Global: 1,538^th place; English: 1,042^nd place)

pdsp.unc.edu

Roth BL, Driscol J. "Bupropion – PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 19 August 2024.

unil.ch (Global: 9,112^th place; English: 7,304^th place)

serval.unil.ch

Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, et al. (October 2021). "Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants" (PDF). The World Journal of Biological Psychiatry. 22 (8): 561–628. doi:10.1080/15622975.2021.1878427. PMID 33977870. S2CID 234472488. Archived (PDF) from the original on 5 May 2022. Retrieved 10 April 2022.

uspto.gov (Global: 1,459^th place; English: 991^st place)

patft.uspto.gov

Mehta NB (25 June 1974). "United States Patent 3,819,706: Meta-chloro substituted α-butylamino-propiophenones". USPTO. Archived from the original on 7 November 2017. Retrieved 2 June 2008.

vcu.edu (Global: 7,721^st place; English: 4,593^rd place)

scholarscompass.vcu.edu

Shalabi AR (14 December 2017). Structure-Activity Relationship Studies of Bupropion and Related 3-Substituted Methcathinone Analogues at Monoamine Transporters. VCU Scholars Compass (Thesis). doi:10.25772/M4E1-3549. Retrieved 24 November 2024.

web.archive.org (Global: 1^st place; English: 1^st place)

"Bupropion Use During Pregnancy". Drugs.com. Archived from the original on 24 December 2018. Retrieved 24 December 2018.
"TGA eBS – Product and Consumer Medicine Information Licence". Archived from the original on 7 December 2016. Retrieved 9 January 2023.
Brazilian Health Regulatory Agency (Anvisa) (31 March 2023). "RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 – Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 3 August 2023.
"Wellbutrin Product information". Health Canada. 25 April 2012. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
"Zyban Product information". Health Canada. 25 April 2012. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
"Zyban 150 mg prolonged release tablets – Summary of Product Characteristics (SmPC)". (emc). 21 April 2022. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
"Wellbutrin SR – bupropion hydrochloride tablet, film coated". DailyMed. 5 November 2019. Archived from the original on 4 June 2020. Retrieved 6 May 2020.
"Wellbutrin XL- bupropion hydrochloride tablet, extended release". DailyMed. 4 March 2022. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
"Aplenzin – bupropion hydrobromide tablet, extended-release". DailyMed. 2 June 2020. Archived from the original on 26 October 2020. Retrieved 21 October 2020.
"Bupropion hydrochloride EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 18 August 2022. Retrieved 7 March 2023.
"Zyban 150 mg prolonged release film-coated tablets – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 1 August 2013. Archived from the original on 20 July 2017. Retrieved 22 October 2013.
De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E (March 2021). "A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants". Drug Safety. 44 (3): 291–312. doi:10.1007/s40264-020-01027-x. PMID 33354752. S2CID 229357583. Archived from the original on 7 March 2023. Retrieved 17 May 2022.
Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, et al. (October 2021). "Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants" (PDF). The World Journal of Biological Psychiatry. 22 (8): 561–628. doi:10.1080/15622975.2021.1878427. PMID 33977870. S2CID 234472488. Archived (PDF) from the original on 5 May 2022. Retrieved 10 April 2022.
DeBattista C (16 June 2022). "Other Antidepressants: Bupropion, Mirtazapine, and Trazodone". In Nemeroff CB, Schatzberg AF, Rasgon N, Strakowski SM (eds.). The American Psychiatric Association Publishing Textbook of Mood Disorders, Second Edition. American Psychiatric Pub. pp. 365–374. ISBN 978-1-61537-331-4. OCLC 1249799493. Archived from the original on 8 March 2023. Retrieved 27 August 2022.
"Bupropion". PubChem. United States National Library of Medicine – National Center for Biotechnology Information. 28 July 2018. Archived from the original on 29 July 2018. Retrieved 29 July 2018.
Dye LR, Murphy C, Calello DP, Levine MD, Skolnik A (2017). Case Studies in Medical Toxicology: From the American College of Medical Toxicology. Springer. p. 85. ISBN 978-3-319-56449-4. Archived from the original on 29 August 2021. Retrieved 5 June 2020.
Mehta NB (25 June 1974). "United States Patent 3,819,706: Meta-chloro substituted α-butylamino-propiophenones". USPTO. Archived from the original on 7 November 2017. Retrieved 2 June 2008.
"Wellbutrin approval package" (PDF). U.S. Food and Drug Administration (FDA). 30 December 1985. Archived from the original (PDF) on 27 November 2020. Retrieved 5 May 2020.
"Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
Monden R, Roest AM, van Ravenzwaaij D, Wagenmakers EJ, Morey R, Wardenaar KJ, et al. (August 2018). "The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews" (PDF). Journal of Affective Disorders. 235: 393–398. doi:10.1016/j.jad.2018.04.040. hdl:11370/842b1441-d0f3-4797-b95b-3a6a72262150. PMID 29677603. S2CID 5011570. Archived (PDF) from the original on 27 February 2022. Retrieved 13 December 2021.
Clayton AH (2003). "Antidepressant-Associated Sexual Dysfunction: A Potentially Avoidable Therapeutic Challenge". Primary Psychiatry. 10 (1): 55–61. Archived from the original on 4 June 2020. Retrieved 21 March 2013.
"Drug Approval Package: Contrave (naltrexone hydrochloride/bupropion hydrochloride) Extended-Release Tablets NDA #200063". U.S. Food and Drug Administration (FDA). Archived from the original on 4 June 2020. Retrieved 5 May 2020.
"Contrave Extended-Release – naltrexone hydrochloride and bupropion hydrochloride tablet, extended-release". DailyMed. 26 April 2019. Archived from the original on 4 June 2020. Retrieved 5 May 2020.
Alberti S, Chiesa A, Andrisano C, Serretti A (June 2015). "Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis". Journal of Clinical Psychopharmacology. 35 (3): 296–303. doi:10.1097/JCP.0000000000000329. PMID 25874915. S2CID 33102792. Archived from the original on 8 March 2023. Retrieved 13 November 2022.
Levenson M, Holland C. "Antidepressants and suicidality in adults: statistical evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; December 13, 2006)". U.S. Food and Drug Administration (FDA). Archived from the original on 27 September 2007. Retrieved 13 May 2007.
"Highlight os Prescribing Information: CONTRAVE (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets, for oral use" (PDF). Currax Pharmaceuticals LLC. U.S. Food and Drug Administration. August 2020. Archived (PDF) from the original on 19 October 2020. Retrieved 1 December 2020.
Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1" (PDF). J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID 26791601. Archived from the original (PDF) on 9 May 2025.
Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB (June 2006). "A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice". Int Immunopharmacol. 6 (6): 903–7. doi:10.1016/j.intimp.2005.12.007. PMID 16644475. Archived from the original on 16 October 2023. Retrieved 25 October 2023.
"Wellbutrin entry in the Orange Book". U.S. Food and Drug Administration Center for Drug Evaluation and Research. Archived from the original on 25 February 2011. Retrieved 18 August 2007.
"Bupropion (Wellbutrin)". eMedExpert.com. 31 March 2008. Archived from the original on 6 August 2013. Retrieved 20 August 2013.
Whitten L (April 2006). "Bupropion helps people with schizophrenia quit smoking". National Institute on Drug Abuse Research Findings. 20 (5). Archived from the original on 5 August 2007. Retrieved 27 May 2013.
"Drug Approval Package: Wellbutrin XL (Bupropion HCI) NDA #021515". U.S. Food and Drug Administration (FDA). 22 April 2005. Archived from the original on 5 December 2019. Retrieved 4 December 2019.
"Drug Approval Package: Zyban NDA# 020711". U.S. Food and Drug Administration (FDA). 8 August 2003. Archived from the original on 5 December 2019. Retrieved 4 December 2019.
"FDA approval letter" (PDF). U.S. Food and Drug Administration (FDA). 6 December 2006. Archived (PDF) from the original on 1 November 2020. Retrieved 21 October 2020.
"Seasonal affective disorder drug Wellbutrin XL wins approval". CNN. 14 June 2006. Archived from the original on 30 June 2007. Retrieved 19 August 2007.
"Generic drug equality questioned". 12 October 2007. Archived from the original on 20 October 2012. Retrieved 13 October 2007.
Stenson J (12 October 2007). "Report questions generic antidepressant". NBC News. Archived from the original on 11 October 2013. Retrieved 13 October 2007.
"Review of therapeutic equivalence: generic bupropion XL 300 mg and Wellbutrin XL 300 mg". Food and Drug Administration. Archived from the original on 6 June 2011. Retrieved 19 April 2008.
"Budeprion XL 300 mg not therapeutically equivalent to Wellbutrin XL 300 mg". U.S. Food and Drug Administration (FDA). 3 October 2012. Archived from the original on 13 December 2019. Retrieved 23 March 2013. This article incorporates text from this source, which is in the public domain.
Waknine Y (8 May 2008). "FDA Approvals: Advair, Relistor, Aplenzin". Medscape. Archived from the original on 6 July 2022. Retrieved 9 May 2008.
"Drug Approval Package: Aplenzin (Bupropion Hydrobromide) NDA 22108". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 15 August 2020. Retrieved 5 May 2020.
Center for Drug Evaluation and Research. "Application number 22-108 Cross Discipline Team Leader Review" (PDF). accessdata.fda.gov. Archived from the original (PDF) on 28 February 2017.
"Public Health Advisory: FDA requires new boxed warnings for the smoking cessation drugs Chantix and Zyban". U.S. Food and Drug Administration (FDA). 1 July 2009. Archived from the original on 19 October 2010. Retrieved 3 July 2009.
"The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics) suicidal ideation and behavior" (PDF). Drug Safety Newsletter. 2 (1): 1–4. 2009. Archived from the original (PDF) on 11 February 2017. Retrieved 16 December 2019.
"Safety Alerts for Human Medical Products – Chantix (varenicline) and Zyban (bupropion)". Drug Safety Communication – Mental Health Side Effects Revised. U.S. Food and Drug Administration (FDA). 16 December 2016. Archived from the original on 20 December 2016. Retrieved 20 December 2016.
Thomas K, Schmidt MS (2 July 2012). "Glaxo agrees to pay $3 billion in fraud settlement". The New York Times. Archived from the original on 2 March 2017. Retrieved 26 February 2017.
Committee for Medicinal Products for Human Use (CHMP) (24 March 2017). "EMA recommends suspension of medicines due to unreliable studies from Micro Therapeutic Research Labs". European Medicines Agency. Archived from the original on 26 October 2020. Retrieved 26 November 2020.
Committee for Medicinal Products for Human Use (CHMP) (23 March 2017). "Products for which the marketing authorisations are recommended for suspension and marketing authorisation applications which do not satisfy the criteria for authorisation as adopted by the CHMP" (PDF). European Medicines Agency. Archived (PDF) from the original on 19 January 2021. Retrieved 26 November 2020.
"EMA advises companies on steps to take avoid nitrosamines in human medicines". European Medicines Agency (EMA). 26 September 2019. Archived from the original on 11 November 2023. Retrieved 24 October 2023.
Lipanovic D (6 September 2023). "Bupropion to be made available in the UK again from December 2023, says manufacturer". The Pharmaceutical Journal. Archived from the original on 11 October 2023. Retrieved 24 October 2023.
Antidepressant Wellbutrin becomes 'poor man's cocaine' on Toronto streets Archived 26 October 2020 at the Wayback Machine Global News 18 September 2013.
"Постановление Правительства РФ от 30 июня 1998 г. N 681 "Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации" (с изменениями и дополнениями) Resolution of the Government of the Russian Federation of June 30, 1998 N 681 "On approval of the list of narcotic drugs, psychotropic substances and their precursors subject to control in the Russian Federation" (with amendments and additions)". base.garant.ru (in Russian). Гарант Garant (reference and legal system). 30 June 1998. Archived from the original on 20 April 2013. Retrieved 28 April 2019. Эфедрон (меткатинон) и его производные, за исключением производных, включенных в качестве самостоятельных позиций в перечень Ephedrone (methcathinone) and its derivatives, with the exception of derivatives included as independent items in the list.
"Autorisation – ZYBAN L.P. 150 mg, comprimé à libération prolongée". agence-prd.ansm.sante.fr (in French). Archived from the original on 9 April 2023. Retrieved 9 April 2023.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

DeBattista C (16 June 2022). "Other Antidepressants: Bupropion, Mirtazapine, and Trazodone". In Nemeroff CB, Schatzberg AF, Rasgon N, Strakowski SM (eds.). The American Psychiatric Association Publishing Textbook of Mood Disorders, Second Edition. American Psychiatric Pub. pp. 365–374. ISBN 978-1-61537-331-4. OCLC 1249799493. Archived from the original on 8 March 2023. Retrieved 27 August 2022.
Andersen J, Ringsted KB, Bang-Andersen B, Strømgaard K, Kristensen AS (27 October 2015). "Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter". Scientific Reports. 5 (1) 15650. Bibcode:2015NatSR...515650A. doi:10.1038/srep15650. ISSN 2045-2322. PMC 4621520. PMID 26503701.
Ferris RM, Russell A, Tang FL, Topham PA (1991). "Labeling in vivo of sigma receptors in mouse brain with [ 3 H]-(+)-SKF 10,047: Effects of phencyclidine, (+)- and (−)-N-allylnormetazocine, and other drugs". Drug Development Research. 24 (1): 81–92. doi:10.1002/ddr.430240107. ISSN 0272-4391.
Gursahani H, Jolas T, Martin M, Cotier S, Hughes S, Macfadden W, et al. (2023). "Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion". CNS Spectrums. 28 (2): 222. doi:10.1017/S1092852923001396. ISSN 1092-8529. In vitro functional studies showed agonist activity of solriamfetol at human, mouse, and rat TAAR1 receptors. hTAAR1 EC50 values (10–16 μM) were within the clinically observed therapeutic solriamfetol plasma concentration range and overlapped with the observed DAT/NET inhibitory potencies of solriamfetol in vitro. TAAR1 agonist activity was unique to solriamfetol; neither the WPA modafinil nor the DAT/NET inhibitor bupropion had TAAR1 agonist activity.
Strawbridge R, Izurieta E, Day E, Tee H, Young K, Tong CC, et al. (2023). "Peripheral inflammatory effects of different interventions for treatment-resistant depression: A systematic review". Neuroscience Applied. 2 101014. Elsevier BV. doi:10.1016/j.nsa.2022.101014. ISSN 2772-4085. PMC 12244173. PMID 40655965. S2CID 253283525.

Bupropion (English Wikipedia)

bindingdb.org (Global: low place; English: low place)

books.google.com (Global: 3rd place; English: 3rd place)

cam.ac.uk (Global: 670th place; English: 480th place)

api.repository.cam.ac.uk

canada.ca (Global: 1,712th place; English: 1,063rd place)

health-products.canada.ca

cardiff.ac.uk (Global: low place; English: 7,039th place)

orca.cardiff.ac.uk

clincalc.com (Global: 3,912th place; English: 2,496th place)

cnn.com (Global: 28th place; English: 26th place)

d1wqtxts1xzle7.cloudfront.net (Global: low place; English: low place)

doi.org (Global: 2nd place; English: 2nd place)

drugabuse.gov (Global: 6,166th place; English: 5,476th place)

drugbank.com (Global: low place; English: low place)

go.drugbank.com

drugs.com (Global: 399th place; English: 333rd place)

emedexpert.com (Global: low place; English: low place)

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

exlibrisgroup.com (Global: 9,042nd place; English: 5,814th place)

unisa.alma.exlibrisgroup.com

fda.gov (Global: 447th place; English: 338th place)

accessdata.fda.gov

fda.gov

fiocruz.br (Global: low place; English: low place)

arca.fiocruz.br

garant.ru (Global: 1,937th place; English: 7,777th place)

base.garant.ru

globalnews.ca (Global: 985th place; English: 583rd place)

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

in.gov.br (Global: 3,151st place; English: 5,932nd place)

lww.com (Global: 2,769th place; English: 3,314th place)

journals.lww.com

medicines.org.uk (Global: 3,823rd place; English: 2,387th place)

medscape.com (Global: 719th place; English: 636th place)

mhmedical.com (Global: 6,846th place; English: 4,957th place)

accessmedicine.mhmedical.com

nbcnews.com (Global: 137th place; English: 101st place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

nytimes.com (Global: 7th place; English: 7th place)

peoplespharmacy.com (Global: low place; English: low place)

pharmaceutical-journal.com (Global: low place; English: low place)

primarypsychiatry.com (Global: low place; English: low place)

psu.edu (Global: 207th place; English: 136th place)

citeseerx.ist.psu.edu

sante.fr (Global: 8,603rd place; English: low place)

agence-prd.ansm.sante.fr

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

tga.gov.au (Global: 3,984th place; English: 2,622nd place)

ebs.tga.gov.au

unc.edu (Global: 1,538th place; English: 1,042nd place)

pdsp.unc.edu

unil.ch (Global: 9,112th place; English: 7,304th place)

serval.unil.ch

uspto.gov (Global: 1,459th place; English: 991st place)

patft.uspto.gov

vcu.edu (Global: 7,721st place; English: 4,593rd place)

scholarscompass.vcu.edu

web.archive.org (Global: 1st place; English: 1st place)

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

books.google.com (Global: 3^rd place; English: 3^rd place)

cam.ac.uk (Global: 670^th place; English: 480^th place)

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

cardiff.ac.uk (Global: low place; English: 7,039^th place)

clincalc.com (Global: 3,912^th place; English: 2,496^th place)

cnn.com (Global: 28^th place; English: 26^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugabuse.gov (Global: 6,166^th place; English: 5,476^th place)

drugs.com (Global: 399^th place; English: 333^rd place)

europa.eu (Global: 68^th place; English: 117^th place)

exlibrisgroup.com (Global: 9,042^nd place; English: 5,814^th place)

fda.gov (Global: 447^th place; English: 338^th place)

garant.ru (Global: 1,937^th place; English: 7,777^th place)

globalnews.ca (Global: 985^th place; English: 583^rd place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

in.gov.br (Global: 3,151^st place; English: 5,932^nd place)

lww.com (Global: 2,769^th place; English: 3,314^th place)

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

medscape.com (Global: 719^th place; English: 636^th place)

mhmedical.com (Global: 6,846^th place; English: 4,957^th place)

nbcnews.com (Global: 137^th place; English: 101^st place)

nih.gov (Global: 4^th place; English: 4^th place)

nytimes.com (Global: 7^th place; English: 7^th place)

psu.edu (Global: 207^th place; English: 136^th place)

sante.fr (Global: 8,603^rd place; English: low place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

unc.edu (Global: 1,538^th place; English: 1,042^nd place)

unil.ch (Global: 9,112^th place; English: 7,304^th place)

uspto.gov (Global: 1,459^th place; English: 991^st place)

vcu.edu (Global: 7,721^st place; English: 4,593^rd place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 5^th place; English: 5^th place)